HERCULES TECHNOLOG	Y GROWTH CAPITAL INC
Form 10-Q	
May 07, 2015	

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

 $x\,QUARTERLY$ REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended March 31, 2015

OR

"TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 814-00702

HERCULES TECHNOLOGY GROWTH

CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Maryland 743113410 (State or Jurisdiction of (IRS Employer

Incorporation or Organization) Identification No.)

400 Hamilton Ave., Suite 310 (Zip Code)

Palo Alto, California

(Address of Principal Executive Offices)

(650) 289-3060

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes "No"

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer

Non-accelerated filer " Smaller reporting company " Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No $\,$ x

On May 4, 2015, there were 72,584,695 shares outstanding of the Registrant's common stock, \$0.001 par value.

FORM 10-Q TABLE OF CONTENTS

PART :	I. FINANCIAL INFORMATION	3
Item 1.	Consolidated Financial Statements	3
	Consolidated Statement of Assets and Liabilities as of March 31, 2015 (unaudited) and December 31, 2014	3
	Consolidated Statement of Operations for the three month periods ended March 31, 2015 and 2014 (unaudited)	5
	Consolidated Statement of Changes in Net Assets for the three month periods ended March 31, 2015 and 2014 (unaudited)	6
	Consolidated Statement of Cash Flows for the three month periods ended March 31, 2015 and 2014 (unaudited)	7
	Consolidated Schedule of Investments as of March 31, 2015 (unaudited)	8
	Consolidated Schedule of Investments as of December 31, 2014	22
	Notes to Consolidated Financial Statements (unaudited)	36
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	64
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	98
Item 4.	Controls and Procedures	99
PART :	II. OTHER INFORMATION Legal Proceedings	100 100

Item 1.

	Item 1A. Risk Factors	100
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	101
Item 3.	Defaults Upon Senior Securities	101
Item 4.	Mine Safety Disclosures	101
Item 5.	Other Information	101
Item 6.	<u>Exhibits</u>	102
<u>SIGNA</u>	<u>TURES</u>	103
2		

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the "Company," "Hercules," "we," "us" and "our" refer to Hercules Technology Growth Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts unless the context otherwise requires.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(unaudited)

(dollars in thousands, except per share data)

	March 31,	December
	2015	31, 2014
Assets		
Investments:		
Non-control/Non-affiliate investments (cost of \$1,154,801 and \$1,019,799, respectively)	\$1,150,639	\$1,012,738
Affiliate investments (cost of \$16,007 and \$15,538, respectively)	10,782	7,999
Total investments, at value (cost of \$1,170,808 and \$1,035,337, respectively)	1,161,421	1,020,737
Cash and cash equivalents	171,756	227,116
Restricted cash	21,949	12,660
Interest receivable	9,102	9,453
Other assets	22,860	29,257
Total assets	\$1,387,088	\$1,299,223
Liabilities		
Accounts payable and accrued liabilities	\$9,320	\$14,101
Long-term Liabilities (Convertible Senior Notes)	17,375	17,345
2017 Asset-Backed Notes	4,203	16,049
2021 Asset-Backed Notes	129,300	129,300
2019 Notes	170,364	170,364
2024 Notes	103,000	103,000
Long-term SBA Debentures	190,200	190,200
Total liabilities	\$623,762	\$640,359
Net assets consist of:		
Common stock, par value	73	65
Capital in excess of par value	760,034	657,233
Unrealized depreciation on investments	(11,462	
Accumulated realized gains on investments	17,391	14,079
Undistributed net investment income (Distributions in excess of net investment income)	(2,710	4,563
Total net assets	\$763,326	\$658,864
Total liabilities and net assets	\$1,387,088	\$1,299,223
	, , , , , , , , , , , , , , , , , , , ,	, , ,

Shares of common stock outstanding (\$0.001 par value, 100,000,000 authorized)	72,891	64,715
Net asset value per share	\$10.47	\$10.18

See notes to consolidated financial statements.

The following table presents the assets and liabilities of our consolidated securitization trusts for the asset-backed notes (see Note 4), which are variable interest entities ("VIE"). The assets of our securitization VIEs can only be used to settle obligations of our consolidated securitization VIEs, these liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statement of Assets and Liabilities above.

	March	December
(Dollars in thousands)	31, 2015	31, 2014
Assets		
Restricted Cash	\$21,949	\$12,660
Total investments, at value (cost of \$261,304 and \$296,314, respectively)	262,394	291,464
Total assets	\$284,343	\$304,124
Liabilities		
Asset-Backed Notes	\$133,503	\$145,349
Total liabilities	\$133,503	\$145,349

See notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

(in thousands, except per share data)

	For the TI Months E March 31	inded,
	2015	2014
Investment income:		
Interest income	\$20.450	
Non-Control/Non-Affiliate investments	\$30,459	\$29,382
Affiliate investments	100	1,464
Total interest income	30,559	30,846
Fees		
Non-Control/Non-Affiliate investments	1,934	4,913
Affiliate investments	1	11
Total fees	1,935	4,924
Total investment income	32,494	35,770
Operating expenses:		
Interest	7,854	7,148
Loan fees	1,513	2,076
General and administrative	3,618	2,461
Employee Compensation:		
Compensation and benefits	3,796	4,221
Stock-based compensation	2,719	1,560
Total employee compensation	6,515	5,781
Total operating expenses	19,500	17,466
Loss on debt extinguishment (Long-term Liabilities - Convertible Senior Notes)	(1)	
Net investment income	12,993	18,304
Net realized gain on investments		
Non-Control/Non-Affiliate investments	3,312	4,872
Total net realized gain on investments	3,312	4,872
Net increase in unrealized appreciation (depreciation) on investments		
Non-Control/Non-Affiliate investments	3,301	(1,038)
Affiliate investments	2,313	47
Total net unrealized appreciation (depreciation) on investments	5,614	(991)
Total net realized and unrealized gain (loss)	8,926	3,881
Net increase in net assets resulting from operations	\$21,919	
The mercuse in her assets resulting from operations	Ψ21,717	Ψ 22,103
Net investment income before investment gains and losses per common share:		
Basic	\$0.20	\$0.30
Change in net assets per common share:		

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Basic	\$0.33	\$0.36
Diluted	\$0.33	\$0.35
Weighted average shares outstanding		
Basic	63,783	60,870
Diluted	64,163	62,695
Dividends declared per common share:		
Basic	\$0.31	\$0.31

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)

	Common Shares			(Depreciat	on Realized	Undistribut net investm income/ ted (Distributio in excess of ssesi)nvestment nentincome)	ent	Taxes
Balance at December 31 2013	61,837	\$62	\$656,594	\$ 3,598	\$ (15,240) \$ 5,335	\$ (342) \$650,007
Net increase (decrease) in net assets resulting from								
operations	_		_	(991) 4,872	18,304	_	22,185
Issuance of common stock due to				(C)		-,-		
stock option exercises	62	_	727	_	_	_	_	727
Retired shares from net issuance	(48)	· —	(748)				_	(748)
Retired shares for restricted stock								
vesting	(120)	· —	(1,724)	_	_	_	_	(1,724)
Issuance of common stock as								
stock dividend	29	_	440	_	_	_		440
Dividends distributed	_	_	_	_		(19,165) —	(19,165)
Stock-based			1.500					1 500
compensation Balance at March 31,			1,580	_	<u>—</u>	_	_	1,580
2014	61,760	\$62	\$656,869	\$ 2,607	\$ (10,368) \$ 4,474	\$ (342) \$653,302
Balance at December 31	• •							
2014	64,715	\$65	\$657,233) \$ 14,079	\$ 4,905	\$ (342) \$658,864
Net increase (decrease) in net assets	_	_	_	5,614	3,312	12,993	_	21,919

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

1.º C								
resulting from								
operations								
Public offering, net of	7.501	0	100.004					100.002
offering expenses	7,591	8	100,084				_	100,092
Issuance of common								
stock due to								
-414'	2.4		406					406
stock option exercises	34	_	406	_	_	_	_	406
Retired shares from net	(07		(401	`				(401
issuance	(27) —	(401) —			<u>—</u>	(401)
Issuance of common								
stock under								
	500							
restricted stock plan Retired shares for	580	_	_	_	-	_		_
restricted stock								
vesting	(42) —	(591) —	_	_		(591)
Issuance of common								,
stock as								
stock dividend	40	_	562	_	_	_	_	562
Dividends distributed	_	_	_			(20,266) —	(20,266)
Stock-based						•	•	, , ,
compensation	_	_	2,741	_	_	_	_	2,741
Balance at March 31,								
2015	72,891	\$73	\$760,034	\$ (11,462) \$ 17,391	\$ (2,368) \$ (342) \$763,326

CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

Cash flows from operating activities: 2015 2014 Net increase in net assets resulting from operations \$21,919 \$22,185 Adjustments to reconcile net increase in net assets resulting from
Adjustments to reconcile net increase in net assets resulting from
operations to net cash provided by (used in) operating activities:
Purchase of investments (209,387) (113,887)
Principal and fee payments received on investments 75,368 135,008
Proceeds from the sale of investments 7,001 7,598
Net unrealized depreciation (appreciation) on investments (5,614) 991
Net realized gain on investments (3,312) (4,872)
Accretion of paid-in-kind principal (665) (659)
Accretion of loan discounts (1,356) (3,378)
Accretion of loan discount on Convertible Senior Notes 62 271
Loss on debt extinguishment (Long-term Liabilities - Convertible Senior Notes) 1 —
Payment of loan discount on Convertible Senior Notes (2) —
Accretion of loan exit fees (2,767) (2,411)
Change in deferred loan origination revenue 1,540 (457)
Unearned fees related to unfunded commitments 527 (125)
Amortization of debt fees and issuance costs 1,288 1,913
Depreciation 58 54
Stock-based compensation and amortization of restricted stock grants 2,741 1,579
Change in operating assets and liabilities:
Interest and fees receivable 351 786
Prepaid expenses and other assets 2,674 (3,401)
Accounts payable (504) (41)
Accrued liabilities (3,978) (5,307)
Net cash provided by (used in) operating activities (114,055) 35,847
Cash flows from investing activities:
Purchases of capital equipment (42) (4
Reduction of (investment in) restricted cash (9,289) 1,487
Net cash provided by (used in) investing activities (9,331) 1,483
Cash flows from financing activities:
Issuance of common stock, net 100,092 (135)
Issuance (retirement) of employee shares (586) (1,738)

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Dividends paid	(19,704)	(18,725)
Repayments of 2017 Asset-Backed Notes	(11,846)	(25,775)
Repayments of Long-Term SBA Debentures		(34,800)
Cash Paid for redemption of Convertible Senior Notes	(30) —
Fees paid for credit facilities and debentures	100	13
Net cash provided by (used in) financing activities	68,026	(81,160)
Net decrease in cash and cash equivalents	(55,360)	(43,830)
Cash and cash equivalents at beginning of period	227,116	268,368
Cash and cash equivalents at end of period	\$171,756	\$224,538
Supplemental non-cash investing and financing activities:		
Dividends Reinvested	\$562	\$440
Paid-in-kind Principal	\$1,356	\$1,207

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of			Principal		
ortfolio Company	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Debt Investment							
Communications & Ne	etworking						
-5 Years Maturity	_						
OpenPeak, Inc. (10)(12)	Communications & Networking	Senior Secured	April 2017	Interest rate PRIME + 8.75%			
				or Floor rate of 12.00%	\$11,680	\$11,864	\$11,981
kyCross, Inc. (12)(13)	Communications & Networking	Senior Secured	January 2018	Interest rate PRIME + 9.70%			
				or Floor rate of 12.95%	\$22,000	21,551	17,775
ubtotal: 1-5 Years Ma						33,415	29,756
ubtotal: Communicati	ions &						
Vetworking (3.90%)*						33,415	29,756
0.70	D 1 .						
Consumer & Business	Products						
-5 Years Maturity	Consumer &	Senior	Dagamhar 2017	Interest rate PRIME + 6.75%			
Intenna79 (p.k.a. ong Research	Business	Secured	December 2017	interest rate PRIME + 0.75%			
Corporation) ⁽¹¹⁾⁽¹²⁾⁽¹³⁾		Secured		or Floor rate of 10.00%,			
orporation).	Troducts			of 1 1001 fate of 10.00%;			
				PIK Interest 2.50%	\$4,869	4,798	4,944
	Consumer &	Senior	June 2016	Interest rate PRIME + 7.75%	, ,	,	,
	Business	Secured					
	Products			or Floor rate of 11.00%	\$183	183	182
'otal Antenna79 (p.k.a	ı. Pong						
Research Corporation)					\$5,052	4,981	5,126
luc, Inc. ⁽⁸⁾	Consumer &	Convertible	March 2017	Interest rate FIXED 4.00%			
	Business Products	Senior Note			¢ 100	100	100
ronPlanet, Inc. (12)	Consumer &	Senior	Navambar 2017	Interest rate PRIME + 6.20%	\$100	100	100
rompianet, inc.(12)	Business	Secured	November 2017	Interest rate PRIME + 0.20%			
	Products	Secureu		or Floor rate of 9.45%	\$37,500	36,911	36,911
he Neat	Consumer &	Senior	September 2017	Interest rate PRIME + 7.75%		19,624	19,536
Company ⁽¹¹⁾⁽¹²⁾⁽¹³⁾	Business	Secured	September 2017	interest rate i Mivil + 1.13/0	Ψ20,111	17,027	17,550
- Janpanij	~ WOIII COO	200100					

	Products			or Floor rate of 11.00%,			
				PIK Interest 1.00%			
ubtotal: 1-5 Years Ma	•					61,616	61,673
ubtotal: Consumer & roducts (8.08%)*	Business					61,616	61,673
.							
Drug Delivery -5 Years Maturity							
AcelRx harmaceuticals,	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 3.85%			
nc. ⁽⁹⁾⁽¹⁰⁾⁽¹²⁾⁽¹³⁾				or Floor rate of 9.10%	\$25,000	25,020	25,261
Agile Therapeutics, nc ⁽¹²⁾	Drug Delivery	Senior Secured	December 2018	Interest rate PRIME + 5.75%			
				or Floor rate of 9.00%	\$16,500	15,904	15,904
BIND Therapeutics, nc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Senior Secured	July 2018	Interest rate PRIME + 5.10%			
				or Floor rate of 8.35%	\$15,000	14,787	14,051
BioQuiddity ncorporated ⁽¹²⁾	Drug Delivery	Senior Secured	May 2018	Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$7,500	7,490	7,490
lelator harmaceuticals,	Drug Delivery	Senior Secured	June 2018	Interest rate PRIME + 6.50%			
nc. ⁽¹⁰⁾⁽¹²⁾	D D !!		Y 0015	or Floor rate of 9.75%	\$15,000	14,846	14,886
Celsion Corporation ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 8.00%			
D: 1	D D !!	a .	N 1 2015	or Floor rate of 11.25%	\$9,122	9,071	9,243
Dance Biopharm, nc. (12)(13)	Drug Delivery	Senior Secured	November 2017	Interest rate PRIME + 7.40%	†2 (1)	2 (10	2 (1 1
ldas Thomanoutics	Daya Daliyaan	Conion	March 2019	or Floor rate of 10.65%	\$3,616	3,610	3,614
ldge Therapeutics, nc. ⁽¹²⁾	Drug Delivery	Senior Secured	March 2018	Interest rate PRIME + 5.95%		~ 00.4	7 000
Scalat Company (12)	Dana Dalinama	Camian	I1 2010	or Floor rate of 10.45%	\$6,000	5,894	5,820
Igalet Corporation ⁽¹²⁾	Drug Denvery	Senior Secured	July 2018	Interest rate PRIME + 6.15%	¢ 15 000	14764	14764
Veos Therapeutics,	Drug Delivery	Senior	October 2017	or Floor rate of 9.40% Interest rate PRIME + 7.25%	\$15,000	14,764	14,764
nc. ⁽¹²⁾⁽¹³⁾	Drug Delivery	Secured	October 2017		¢ 10,000	0.947	0.047
	Drug Delivery	Senior	October 2017	or Floor rate of 10.50% Interest rate FIXED 9.00%	\$10,000	9,847	9,947
	Diag Delivery	Secured	OCTOOC! 2017	11101001 1att 1 1/ALD 7.00 /0	\$10,000	10,000	9,874
otal Neos Therapeutic	es, Inc.				\$20,000	19,847	19,821
Losano Pharma, nc. ⁽¹⁰⁾⁽¹²⁾	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 6.80%			
				or Floor rate of 12.05%	\$3,652	3,580	3,601
ubtotal: 1-5 Years Ma						134,813	134,455
ubtotal: Drug Deliver	y (17.61%)*					134,813	134,455

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		_					
		Type of			Duin ain al		
olio Company	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Principal Amount		Value
Discovery & Development	Sub Industry	Investment	Watarry Date	Illiciest Ruic und 1 1001	Hillouit	Cost	¥ 11100
r 1 Year Maturity							
Pharmaceuticals,)(10)(12)(13)	Drug Discovery &	Senior Secured	December 2015	Interest rate PRIME + 7.15%			
	Development	5000101		or Floor rate of 11.90%	\$8,854	\$8,854	\$8,85
ert Pharmaceuticals, Inc. (10)	Drug	Senior Secured	October 2015	Interest rate PRIME + 3.25%	7 - / -	4 5,-	7
	Development			or Floor rate of 8.50%	\$5,086	5,070	5,07
ed, Incorporated ⁽¹⁰⁾⁽¹²⁾	Drug Discovery &	Senior Secured	January 2016	Interest rate PRIME + 4.75%			
	Development			or Floor rate of 9.25%	\$25,000	24,958	24,9
tal: Under 1 Year Maturity						38,882	38,8
ears Maturity							
IA Biologics, Inc. (10)(11)(12)	Drug Discovery &		December 2017	Interest rate PRIME + 3.00%			
	Development			or Floor rate of 8.75%,			
				PIK Interest 1.95%	\$15,225	15,011	15,2
Pharmaceuticals,)(10)(12)(13)	Drug Discovery &	Senior Secured	January 2018	Interest rate PRIME + 6.65%			
	Development			or Floor rate of 11.90%	\$10,000	9,846	9,91
don Corporation ⁽¹²⁾⁽¹³⁾	Drug Discovery &	Senior Secured	February 2018	Interest rate PRIME + 5.00%			
	Development			or Floor rate of 8.25%	\$10,000	10,106	10,1
ora, Inc. ⁽¹⁰⁾⁽¹²⁾	•	Senior Secured	April 2018	Interest rate PRIME + 6.30%			
	Development			or Floor rate of 9.55%	\$18,000	18,035	18,2
cor Inc. ⁽¹²⁾	•	Senior Secured	August 2017	Interest rate PRIME + 4.70%			
	Development			or Floor rate of 7.95%	\$7,500	7,411	7,38
ean Pharma Inc.(12)	Drug Discovery &	Senior Secured	July 2018	Interest rate PRIME + 4.05%			
	Development			or Floor rate of 7.30%	\$15,000	14,718	14,7
eland BioLabs, Inc. (12)(13)			January 2017	Interest rate LIBOR + 6.20%	\$1,702	1,956	1,91

4							
	C	Senior Secured		or Floor rate of 10.45%			
BioPharma Corp. (p.k.a. Cell apeutics, Inc.) ⁽¹⁰⁾⁽¹²⁾	Drug Discovery &			Interest rate PRIME + 8.00%			
	C	Senior Secured		or Floor rate of 11.25% Interest rate PRIME + 6.75%	\$8,117	8,638	8,61
	Development			or Floor rate of 10.00%	\$4,030	4,110	4,09
	Discovery &	Senior Secured		Interest rate PRIME + 8.00%			21
	Development			or Floor rate of 11.25%	\$4,030	4,110	4,09
CTI BioPharma Corp. I. Cell Therapeutics, Inc.)					\$16,177	16,858	16,8
vax Technologies ⁽⁹⁾⁽¹²⁾	Discovery &	Secured	•	Interest rate PRIME + 6.50%			
	Development			or Floor rate of 9.75%	\$10,000	9,983	9,98
s Biopharmaceuticals,	Discovery &	Senior Secured	1	Interest rate PRIME + 4.70%			
(10)(10)	Development			or Floor rate of 7.95%	\$7,500	7,345	7,46
cea Biosciences, Inc. (10)(12)	Discovery &	Senior Secured	•	Interest rate PRIME + 4.00%			
(12)	Development			or Floor rate of 7.25%	\$12,000	11,881	11,8
nta Therapeutics ⁽¹²⁾	Discovery &	Senior Secured		Interest rate PRIME + 5.00%			
T 1 T 141,	Development	~ .		or Floor rate of 8.25%	\$20,000	19,429	19,4
netics, Inc. (p.k.a. Lithera, 2)(13)	Discovery &	Senior Secured	Ž	Interest rate PRIME + 5.75%			
	Development	~ .		or Floor rate of 9.00%	\$10,000	9,806	9,82
imack Pharmaceuticals,	Discovery &	Senior Secured		Interest rate PRIME + 7.30%			10.4
	Development	0 1		or Floor rate of 10.55%	\$40,000	40,515	40,5
alstem, Inc. ⁽¹²⁾⁽¹³⁾	Discovery &		•	Interest rate PRIME + 6.75%	† 0. 400	200	2.26
D M (4)(9)(10)(12)	Development	Ci.a.		or Floor rate of 10.00%	\$9,489	9,389	9,38
ure B.V. (4)(9)(10)(12)	Discovery &	Senior Secured		Interest rate PRIME + 5.00%	* 20 000	10.070	20.1
IA Corporation ⁽⁹⁾⁽¹²⁾⁽¹³⁾	Development	Carion		or Floor rate of 10.25% Interest rate PRIME + 6.15%	\$20,000	19,878	20,2
IA Corporation	Discovery &	Senior Secured		Interest rate PRIME + 6.15% or Floor rate of 9.40%	¢20,000	19,536	10 (
tal: 1-5 Years Maturity	Development			or Floor rate of 9.40%	\$20,000	19,536 241,703	19,5 242
otal: Drug Discovery & Devel	lopment						
7%)*						280,585	281
· · · · · · · · · · · · · · · · · · ·							
ronics & Computer Hardware	9						
ears Maturity							

October 2016

Interest rate LIBOR + 8.75% \$267

or Floor rate of 12.00%,

s Technologies, Inc.⁽⁷⁾⁽¹¹⁾

Electronics & Senior

Secured

Computer

Hardware

18

PIK Interest 4.00%

tal: 1-5 Years Maturity	180	—
otal: Electronics & Computer Hardware		
%)*	180	—

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of					
Portfolio					Principal		
Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Energy Technology	/						
Under 1 Year Matu	•						
Fluidic, Inc. (10)(12)	Energy	Senior	March 2016	Interest rate PRIME + 8.00%			
	Technology	Secured					
~ .	_			or Floor rate of 11.25%	\$2,981	\$3,081	\$3,081
Stion	Energy	Senior	March 2016	Interest rate PRIME + 8.75%			
Corporation ⁽⁵⁾⁽¹²⁾	Technology	Secured		512.000	0.2.462	2.462	1.600
TAGE	Г	c :	D 1 2015	or Floor rate of 12.00%	\$3,462	3,462	1,600
TAS Energy, Inc. ⁽¹⁰⁾⁽¹²⁾	Energy	Senior	December 2015	Interest rate PRIME + 7.75%			
Inc.(10)(12)	Technology	Secured		or Floor rate of 11.00%	¢ 6 1 4 0	6,242	6,242
Subtotal: Under 1	Voor Moturity			or Floor rate of 11.00%	\$6,149	12,785	10,923
1-5 Years Maturity	•					12,763	10,923
Agrivida,	Energy	Senior	December 2016	Interest rate PRIME + 6.75%			
Inc. (12)(13)	Technology	Secured	December 2010	interest rate 1 Kivil 1 0.73 %			
me.	reemiology	Secured		or Floor rate of 10.00%	\$4,921	5,016	4,969
American	Energy	Senior	November 2016	Interest rate PRIME + 7.25%	¥ .,>=1	0,010	.,,, 0,,
Superconductor	Technology	Secured					
Corporation ⁽¹⁰⁾⁽¹²⁾	e,			or Floor rate of 11.00%	\$6,667	6,964	6,843
•	Energy	Senior	March 2017	Interest rate PRIME + 7.75%			·
	Technology	Secured					
				or Floor rate of 11.00%	\$1,500	1,460	1,446
Total American							
Superconductor Co	•				\$8,167	8,424	8,289
Amyris, Inc. (9)(12)	Energy	Senior	February 2017	Interest rate PRIME + 6.25%			
	Technology	Secured					
				or Floor rate of 9.50%	\$25,000	25,000	25,458
	Energy	Senior	February 2017	Interest rate PRIME + 5.25%			
	Technology	Secured				- 000	7 000
TD - 1 A				or Floor rate of 8.50%	\$5,000	5,000	5,092
Total Amyris, Inc.	F	C :	M	Laterate DDIME : 10.459	\$30,000	30,000	30,550
Modumetal, Inc. ⁽¹²⁾	Energy	Senior	March 2017	Interest rate PRIME + 10.45%			
IIIC.(12)	Technology	Secured		or Floor rate of 13.70%	\$2,708	2,760	2,744
				01 1 1001 Tate 01 15./0%	$\varphi \angle, /0\delta$	2,700	2,744

Polyera Corporation ⁽¹²⁾⁽¹³⁾	Energy Technology	Senior Secured	June 2016	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$3,080	3,272	3,258
	Energy Technology	Senior Secured	April 2018	Interest rate PRIME + 6.70%			
				or Floor rate of 9.95%	\$3,000	2,904	2,904
Total Polyera Corp	oration				\$6,080	6,176	6,162
Sungevity Development,	Energy Technology	Senior Secured	October 2017	Interest rate PRIME + 3.70%			
LLC				or Floor rate 6.95%	\$25,000	23,963	23,963
	Energy Technology	Senior Secured	April 2016	Interest rate PRIME + 3.70%			
				or Floor rate 6.95%	\$16,017	16,017	16,017
Total Sungevity Do	•				\$41,017	39,980	39,980
Subtotal: 1-5 Years	•					92,356	92,694
Subtotal: Energy T (13.57%)*	echnology					105,141	103,617
Healthcare Service 1-5 Years Maturity							
Chromadex	Healthcare	Senior	April 2018	Interest rate PRIME + 6.10%			
Corporation ⁽¹²⁾⁽¹³⁾	Services, Other	Secured		or Floor rate of 9.35%	\$2,500	2,427	2,446
InstaMed	Healthcare	Senior	March 2018	Interest rate PRIME + 6.75%	Ψ2,300	2,727	2,440
Instanted	Heartmeare	Semoi	17141011 2010	interest rate i territa i 0.75 /c			
Communications,	Services,	Secured		or Floor rate of 10 00%	\$5,000	5 061	5 011
LLC ⁽¹²⁾⁽¹³⁾	Other	Secured		or Floor rate of 10.00%	\$5,000	5,061 7 488	5,011 7 457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years	Other S Maturity	Secured		or Floor rate of 10.00%	\$5,000	5,061 7,488	5,011 7,457
LLC ⁽¹²⁾⁽¹³⁾	Other S Maturity	Secured		or Floor rate of 10.00%	\$5,000	•	
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)*	Other s Maturity re Services,	Secured		or Floor rate of 10.00%	\$5,000	7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)*	Other s Maturity re Services,	Secured		or Floor rate of 10.00%	\$5,000	7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Servic Under 1 Year Matu	Other s Maturity re Services, es		May 2015		\$5,000	7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Servic Under 1 Year Matu Eccentex	Other s Maturity re Services, es urity Information	Senior	May 2015	or Floor rate of 10.00% Interest rate PRIME + 7.00%	\$5,000	7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Servic Under 1 Year Matu	Other s Maturity re Services, es		May 2015	Interest rate PRIME + 7.00%		7,488 7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Servic Under 1 Year Matu Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾	Other s Maturity re Services, es urity Information Services	Senior	May 2015		\$5,000 \$84	7,488	7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Servic Under 1 Year Matu Eccentex	Other s Maturity re Services, es urity Information Services Year Maturity	Senior	May 2015	Interest rate PRIME + 7.00%		7,488 7,488	7,457 7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI	Other s Maturity re Services, es urity Information Services Year Maturity Information	Senior Secured	·	Interest rate PRIME + 7.00%		7,488 7,488	7,457 7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Matu Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1-5 Years Maturity	Other s Maturity re Services, es urity Information Services Year Maturity	Senior Secured	·	Interest rate PRIME + 7.00% or Floor rate of 10.25%	\$84	7,488 7,488 99 99	7,457 7,457 99 99
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI	Other s Maturity re Services, es urity Information Services Year Maturity Information Services Information	Senior Secured Senior Secured Senior	December 2016	Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 7.00%		7,488 7,488	7,457 7,457
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI	Other s Maturity re Services, es urity Information Services Year Maturity Information Services	Senior Secured Senior Secured	December 2016	Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 7.00% or Floor rate of 10.25%	\$84	7,488 7,488 99 99	7,457 7,457 99 99
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI	Other s Maturity re Services, es urity Information Services Year Maturity Information Services Information	Senior Secured Senior Secured Senior	December 2016	Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 5.75% or Floor rate of 9.00%,	\$84 \$14,612	7,488 7,488 99 99 14,612	7,457 7,457 99 99 14,612
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI Inc. ⁽⁴⁾⁽⁹⁾⁽¹¹⁾⁽¹²⁾	other s Maturity re Services, es arity Information Services Year Maturity Information Services Information Services	Senior Secured Senior Secured Senior	December 2016	Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 5.75%	\$84 \$14,612 \$15,107	7,488 7,488 99 99 14,612	7,457 7,457 99 99 14,612
LLC ⁽¹²⁾⁽¹³⁾ Subtotal: 1-5 Years Subtotal: Healthcar Other (0.98%)* Information Service Under 1 Year Mate Eccentex Corporation ⁽¹⁰⁾⁽¹²⁾ Subtotal: Under 1 1 1-5 Years Maturity INMOBI	other s Maturity re Services, es arity Information Services Year Maturity Information Services Information Services	Senior Secured Senior Secured Senior	December 2016	Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 7.00% or Floor rate of 10.25% Interest rate PRIME + 5.75% or Floor rate of 9.00%,	\$84 \$14,612	7,488 7,488 99 99 14,612	7,457 7,457 99 99 14,612

or Floor rate of 10.75%

Subtotal: 1-5 Years Maturity	31,443	31,434
Subtotal: Information Services		
(4.13%)*	31,542	31,533

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of			Dula di al		
ortfolio Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal Amount		Value ⁽³⁾
nternet Consumer &			.,				
nder 1 Year Maturit							
ducation			March 2016	Interest rate LIBOR + 12.50%			
ynamics,	& Business	Secured					
LC ⁽¹¹⁾⁽¹³⁾	Services			or Floor rate of 12.50%,			
				DIT 1 1 500	#20.642	\$20.620	\$20.60 (
11a Ima (11)(13)	Internat Congumer	Carion	December 2015		\$20,642	\$20,629	\$20,629
razelle, Inc.(11)(13)	Internet Consumer & Business	Senior Secured	December 2015	Interest rate PRIME + 6.50%			1
	Services			or Floor rate of 9.75%	\$407	407	407
etPlenish ⁽⁷⁾⁽⁸⁾⁽¹³⁾	Internet Consumer		April 2015	Interest rate FIXED 10.00%			
	& Business	Senior Note					
	Services				\$65	65	_
		Senior	September 2015	Interest rate FIXED 10.00%			I
	& Business	Secured			Φ201	272	I
otal NetPlenish	Services				\$381 \$446	373 438	_
otai NetPienisn ectura	Internet Consumer	Senior	May 2014	Interest rate LIBOR + 10.00%	\$440	438	_
orporation ⁽⁷⁾⁽¹¹⁾⁽¹⁴⁾	& Business	Secured	May 2014	IIIICICSI IAIC LIDON + 10.00 /0			ļ
Orporation	Services	Secured		or Floor rate of 13.00%	\$563	563	144
		Senior	May 2014	Interest rate LIBOR + 10.00%	Ψυσυ	303	1
	& Business	Secured	1,2				
	Services			or Floor rate of 13.00%	\$5,000	5,000	1,276
		Senior	May 2014	Interest rate LIBOR + 10.00%			
	& Business	Secured					
	Services			or Floor rate of 13.00%	\$6,468	6,468	1,652
		Senior	May 2014	Interest rate LIBOR + 8.00%			
	& Business	Secured		C11 000			
	Services			or Floor rate of 11.00%,			
				PIK Interest 1.00%	\$9,070	9,070	2,317
otal Tectura Corpora	ation				\$21,101	21,101	5,389
ubtotal: Under 1 Yea						42,575	26,425
-5 Years Maturity							

azelle, Inc. ⁽¹¹⁾⁽¹³⁾	& Business	Senior Secured	July 2017	Interest rate PRIME + 7.00%			
	Services			or Floor rate of 10.25%,			
				PIK Interest 2.50%	\$13,797	13,551	13,643
ıst Fabulous, nc. ⁽¹⁰⁾⁽¹²⁾	Internet Consumer & Business	Senior Secured	February 2017	Interest rate PRIME + 8.25%			
	Services			or Floor rate of 11.50%	\$15,000	14,638	14,938
ightspeed POS, ic. (4)(9)(10)	Internet Consumer & Business	Senior Secured	May 2018	Interest rate PRIME + 3.25%			
2=0.44.45.42.50	Services			or Floor rate of 6.50%	\$2,000	1,987	2,000
eply! Inc. ⁽⁷⁾⁽¹¹⁾⁽¹²⁾	Internet Consumer & Business	Senior Secured	March 2019	Interest rate PRIME + 4.25%			
	Services	a .	1 2010	or Floor rate of 7.50%	\$6,321	5,952	3,212
	Internet Consumer & Business	Senior Secured	March 2019	PIK Interest 2.00%			
. 10 111	Services				\$6,321	6,321	3,411
otal Reply! Inc.	Internation	C :	I1 2010	Lateract and DDIME . (500)	\$12,642	12,273	6,623
apjoy, Inc. ⁽¹²⁾	Internet Consumer & Business	Senior Secured	July 2018	Interest rate PRIME + 6.50%	Φ.20.000	10.406	10.415
7 3 M1 - 4 T (12)	Services	Carata n	Manala 2017	or Floor rate of 9.75%	\$20,000	19,496	19,415
VaveMarket, Inc. (12)	& Business	Senior Secured	March 2017	Interest rate PRIME + 6.50%			
1 1 1 7 37 3	Services			or Floor rate of 9.75%	\$268	271	277
ubtotal: 1-5 Years M	•					62,216	56,896
ubtotal: Internet Cor ervices (10.92%)*	nsumer & Business					104,791	83,321
Iedia/Content/Info							
nder 1 Year Maturit	<u> </u>	a .	D 1 2015	V			
oom Media Group, ic. ⁽¹⁰⁾⁽¹¹⁾	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 5.25%			
	N. 11 (G	a .	D 1 2017	or Floor rate of 8.50%	\$5,060	5,060	5,060
	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 7.25%			
				or Floor rate of 10.50%,			
	_			PIK Interest 3.75%	\$2,024	1,998	1,998
otal Zoom Media G					\$7,084	7,058	7,058
ubtotal: Under 1 Yes	ar Maturity					7,058	7,058
-5 Years Maturity	M 11 /C	G :	A 21.0010	I DDINE FAS			
hapsody iternational,	Media/Content/Info	Senior Secured	April 2018	Interest rate PRIME + 5.25%			
nc.(10)(11)(13)				or Floor rate of 9.00%,			
				PIK interest of 1.50%	\$20,281	19,882	19,699
ubtotal: 1 5 Voore M	Noturity					10 882	10.600

ubtotal: 1-5 Years Maturity

ubtotal: Media/Content/Info (3.51%)*

19,699

26,757

19,882

26,940

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of			Principal		
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Medical Devices & E							
Under 1 Year Maturit							
Home Dialysis Plus,	Medical	Senior	September 2015	Interest rate FIXED 8.00%			
Inc. ⁽¹⁰⁾⁽¹²⁾	Devices & Equipment	Secured			\$500	\$500	\$500
Medrobotics Corporation ⁽¹²⁾⁽¹³⁾	Medical Devices &	Senior Secured	March 2016	Interest rate PRIME + 7.85%			
•	Equipment			or Floor rate of 11.10%	\$2,175	2,287	2,287
Subtotal: Under 1 Ye	ar Maturity					2,787	2,787
1-5 Years Maturity							
Amedica Corporation ⁽⁸⁾⁽¹²⁾⁽¹³⁾	Medical Devices &	Senior Secured	January 2018	Interest rate PRIME + 7.70%			
	Equipment			or Floor rate of 10.95%	\$20,000	19,912	20,153
Aspire Bariatrics, Inc. (12)(13)	Medical Devices &	Senior Secured	April 2018	Interest rate PRIME + 6.00%			
	Equipment			or Floor rate of 9.25%	\$4,000	3,590	3,590
Avedro, Inc. (12)(13)	Medical Devices &	Senior Secured	June 2018	Interest rate PRIME + 6.00%			
	Equipment			or Floor rate of 9.25%	\$12,500	12,096	11,998
Flowonix Medical Incorporated ⁽¹²⁾	Medical Devices &	Senior Secured	May 2018	Interest rate PRIME + 5.25%			
	Equipment			or Floor rate of 10.00%	\$15,000	14,768	14,768
Gamma Medica, Inc. ⁽¹⁰⁾⁽¹²⁾	Medical Devices &	Senior Secured	January 2018	Interest rate PRIME + 6.50%			
	Equipment			or Floor rate of 9.75%	\$4,000	3,907	3,885
Home Dialysis Plus, Inc. (10)(12)	Medical Devices &	Senior Secured	October 2017	Interest rate PRIME + 6.35%			
	Equipment			or Floor rate of 9.60%	\$15,000	14,829	14,693
InspireMD, Inc. (4)(9)(12)	Medical Devices &	Senior Secured	February 2017	Interest rate PRIME + 7.25%			
	Equipment			or Floor rate of 10.50%	\$7,901	8,065	8,029
nContact Surgical, Inc ⁽¹²⁾⁽¹³⁾	Medical Devices &	Senior Secured	November 2018	Interest rate PRIME + 9.25%			
	Equipment			or Floor rate of 9.25%	\$10,000	9,783	9,783

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Quanterix Corporation ⁽¹⁰⁾⁽¹²⁾	Medical Devices &	Senior Secured	February 2018	Interest rate PRIME + 2.75%			
_	Equipment			or Floor rate of 8.00%	\$10,000	9,829	9,873
SonaCare Medical, LLC (p.k.a. US	Medical Devices &	Senior Secured	April 2016	Interest rate PRIME + 7.75%			
HIFU, LLC)(10)(12)	Equipment			or Floor rate of 11.00%	\$875	1,231	1,171
SynergEyes, Inc. ⁽¹²⁾⁽¹³⁾	Medical Devices &	Senior Secured	January 2018	Interest rate PRIME + 7.75%			
	Equipment			or Floor rate of 11.00%	\$5,000	5,087	5,056
ViewRay, Inc.(11)(13)	Medical Devices &	Senior Secured	June 2017	Interest rate PRIME + 7.00%			
	Equipment			or Floor rate of 10.25%,			
				PIK Interest 1.50%	\$13,949	13,701	13,790
Subtotal: 1-5 Years M	l aturity					116,798	116,789
Subtotal: Medical De	vices &						
Equipment (15.67%)	*					119,585	119,576
Semiconductors							
1-5 Years Maturity							
Avnera Corporation ⁽¹⁰⁾⁽¹²⁾	Semiconductors	Senior Secured	April 2017	Interest rate PRIME + 5.75%			
				or Floor rate of 9.00%	\$5,000	5,004	5,016
Subtotal: 1-5 Years N	×					5,004	5,016
Subtotal: Semiconduc	ctors (0.66%)*					5,004	5,016

$HERCULES\ TECHNOLOGY\ GROWTH\ CAPITAL,\ INC.$

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of			Principal		
lio Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount		Valu
are	January J						
1 Year Maturity							
loud Corporation ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	July 2015	Interest rate PRIME + 1.40%			
				or Floor rate of 4.65%	\$3,000	\$3,000	\$3,0
ox, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	July 2015	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$2,000	2,000	2,0
	Software	Senior Secured	August 2015	Interest rate PRIME + 8.75%			
				or Floor rate of 12.00%	\$3,000	2,991	2,9
Clickfox, Inc.					\$5,000	4,991	4,9
e Posse, Inc ^{.(12)(13)}	Software	Senior Secured	June 2015	Interest rate PRIME + 2.00%			
				or Floor rate of 5.25%	\$1,000	1,000	1,0
al: Under 1 Year Maturity						8,991	8,9
ars Maturity							
loud Corporation ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	December 2017	Interest rate PRIME + 3.25%			
				or Floor rate of 6.50%	\$208	208	20
	Software	Senior Secured	July 2017	Interest rate PRIME + 5.50%			
				or Floor rate of 8.75%	\$10,000	9,885	9,8
	Software	Senior Secured	January 2018	Interest rate PRIME + 1.70%			
				or Floor rate of 4.95%	\$3,000	2,950	2,9
CareCloud Corporation					\$13,208	13,043	12
ox, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	March 2018	Interest rate PRIME + 8.25%			
				or Floor rate of 11.50%	\$6,000	5,889	5,6
, Inc. ⁽¹²⁾	Software	Senior Secured	March 2018	Interest rate PRIME + 4.60%			
				or Floor rate of 7.85%	\$9,000	8,894	8,8
tart Games, Inc.	Software	Senior Secured	October 2016	Interest rate PRIME + 8.25%	\$1,356	1,353	1,3

4							
Knowledge Adventure, Inc.)				or Floor rate of 11.50%,			ļ
				PIK Interest 6.50%			!
	Software	Senior Secured	March 2018	Interest rate PRIME + 8.25%			
				or Floor rate of 11.50%,			
				PIK Interest 6.50%	\$11,255	11,330	11,
JumpStart Games, Inc.					*12.611	12 (02	10
Knowledge Adventure, Inc.)		C - C- commod	E 1 2017	T	\$12,611	12,683	12.
ge Systems, Inc. ⁽¹³⁾	Software	Senior Secured	February 2017	Interest rate PRIME + 2.75%		1 110	
	C C	C ' C-owned	E 1 2010	or Floor rate of 6.00%	\$1,118	1,118	1,1
	Software	Senior Secured	February 2019	Interest rate PRIME + 7.25%			
T T				or Floor rate of 10.50%	\$17,500	16,996	16.
Message Systems, Inc.	G 6	C . C	D 12016	DDDAE 7500	\$18,618	18,114	18,
e Posse, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	December 2016	Interest rate PRIME + 7.50%			ļ
(10)/10)				or Floor rate of 10.75%	\$2,615	2,632	2,6
Geosolutions, Inc. (12)(13)	Software	Senior Secured	May 2016	Interest rate PRIME + 5.75%			
				or Floor rate of 10.50%	\$1,947	2,084	2,0
us, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	June 2017	Interest rate PRIME + 5.25%			ļ
				or Floor rate of 8.50%	\$1,500	1,514	1,5
, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	February 2018	Interest rate PRIME + 2.25%			
				or Floor rate of 5.50%	\$3,500	3,372	3,3
	Software	Senior Secured	February 2018	Interest rate PRIME + 4.75%			
				or Floor rate of 8.00%	\$15,000	14,446	14.
Soasta, Inc.					\$18,500	17,818	17,
ı, Inc. ⁽¹²⁾⁽¹³⁾	Software	Senior Secured	July 2017	Interest rate PRIME + 7.00%			
				or Floor rate of 10.25%	\$5,029	5,006	5,0
View Systems, Inc. (11)(12)	Software	Senior Secured	December 2017	Interest rate PRIME + 6.00%			
				or Floor rate of 9.25%,			
				PIK Interest 3.00%	\$10,074	9,861	9,8
commerce, Inc.(12)(13)	Software	Senior Secured	August 2016	Interest rate PRIME + 2.25%	•		
				or Floor Rate of 6.50%	\$4,811	4,811	4,7
	Software	Senior Secured	February 2018	Interest rate PRIME + 6.00%		.,-	
				or Floor Rate of 10.25%	\$7,000	6,723	6,7
Fouchcommerce, Inc.				01 2 11	\$11,811	11,534	11
al: 1-5 Years Maturity						109,072	10
al: Software (15.44%)*						118,063	11

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

		Tomasaf					
ortfolio		Type of			Principal		
ompany	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	$C_{oct}(2)$	Value ⁽³⁾
pecialty Pharmac		Illvesulient	Maturity Date	Therest Nate and Pioor	Amount	COSI-/	v arue ·- /
Inder 1 Year Mat							
ranford	Specialty	Senior Secured	August 2015	Interest rate LIBOR + 8.25%			
	Pharmaceuticals	Semer Sees :	1148450 2012	Interest tast Electric States			
$LC^{(10)(11)(12)(13)}$				or Floor rate of 9.50%	\$2,000	\$2,000	\$2,000
ubtotal: Under 1	Year Maturity					2,000	2,000
-5 Years Maturity	y						
limera ciences, Inc. ⁽¹⁰⁾	Specialty Pharmaceuticals	Senior Secured	May 2018	Interest rate PRIME + 7.65%			
				or Floor rate of 10.90%	\$35,000	34,225	33,856
ranford	Specialty	Senior Secured	February 2017	Interest rate LIBOR + 9.55%			
	Pharmaceuticals						
$LC^{(10)(11)(12)(13)}$				or Floor rate of 10.80%,			
				PIK Interest 1.35%	\$14,101	14,125	14,206
ubtotal: 1-5 Year						48,350	48,062
	y Pharmaceuticals					50.250	5 0.06 2
5.56%)*						50,350	50,062
unaigal Daviaga							
urgical Devices Inder 1 Year Mat							
ransmedics,	•	Canior Secured	November 2015	Interest rate FIXED 12.95%			
nc. ⁽¹⁰⁾⁽¹²⁾	Surgical Devices	Sellioi Securca	November 2015	Illustest fate PIAED 12.95/0	\$5,519	5,473	5,473
ubtotal: Under 1	Year Maturity				4 - ,	5,473	5,473
ubtotal: Surgical						•	
).72%)*						5,473	5,473
otal Debt Investi	ments (138.61%)*					1,084,986	1,058,032

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

		Type of				
Portfolio Company	Sub-Industry	Investment(1)	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Equity Investments	·					
Biotechnology Tools						
NuGEN Technologies, Inc. (13)	Biotechnology Tools	Equity	Preferred			
			Series C	189,394	\$500	\$535
Subtotal: Biotechnology Tools (0.	.07%)*				500	535
Communications & Networking						
GlowPoint, Inc. ⁽³⁾	Communications &	Equity	Common			
	Networking		Stock	114,192	102	104
Peerless Network, Inc.	Communications &	Equity	Preferred			
	Networking		Series A	1,000,000	1,000	6,247
Subtotal: Communications & Net	working (0.83%)*				1,102	6,351
Consumer & Business Products						
Market Force Information, Inc.	Consumer & Business	Equity	Preferred			
	Products		Series B-1	187,970	500	3
	Consumer & Business	Equity	Common			
	Products		Stock	480,261	_	237
Total Market Force Information, l				668,231	500	240
Subtotal: Consumer & Business P	Products (0.03%)*				500	240
Diagnostic						
Singulex, Inc.	Diagnostic	Equity	Common			
			Stock	937,998	750	643
Subtotal: Diagnostic (0.08%)*					750	643
Drug Delivery						
AcelRx Pharmaceuticals, Inc.	Drug Delivery	Equity	Common			
(3)(9)(13)	,		Stock	54,240	108	209
	Drug Delivery	Equity		20,000	9	_

Merrion Pharmaceuticals, Plc (3)(4)(9)			Common Stock			
Neos Therapeutics, Inc.	Drug Delivery	Equity	Preferred	200.000	1.500	1.056
C-14-4-1 D D-1 (0.270)	!		Series C	300,000	1,500	1,856
Subtotal: Drug Delivery (0.27%)	r-				1,617	2,065
Drug Discovery & Development						
Aveo Pharmaceuticals, Inc. (3)(9)(13)	Drug Discovery & Development	Equity	Common Stock	167,864	842	243
Cerecor Inc.	Drug Discovery &	Equity	Preferred	107,804	042	243
	Development		Series B	3,334,445	1,000	762
Cerulean Pharma Inc. (3)	Drug Discovery & Development	Equity	Common Stock	135,501	1,000	1,222
Dicerna Pharmaceuticals, Inc. (3)	Drug Discovery &	Equity	Common	,	-,000	-,
(13)	Development		Stock	142,858	1,000	3,433
Epirus Biopharmaceuticals, Inc.	Drug Discovery &	Equity	Common	200.000	1 000	1.700
` '	Development	E analita	Stock	200,000	1,000	1,790
Genocea Biosciences, Inc. (3)	Drug Discovery & Development	Equity	Common Stock	223,463	2,000	2,650
Inotek Pharmaceuticals	Drug Discovery &	Equity	Common	,	,	,
Corporation (3)	Development		Stock	3,778	1,500	20
Insmed, Incorporated (3)	Drug Discovery &	Equity	Common			
	Development		Stock	70,771	1,000	1,322
Paratek Pharmaceutcals, Inc.	Drug Discovery &	Equity	Common			
(p.k.a. Transcept	Development		Stock			
Pharmaceuticals, Inc.) (3)				31,580	1,744	977
Subtotal: Drug Discovery & Deve	elopment (1.63%)*				11,086	12,419
Electronics & Computer Hardwar	re					
Identiv, Inc. (3)	Electronics &	Equity	Common			
racinity, inc.	Computer Hardware	Equity	Stock	6,700	34	57
Subtotal: Electronics & Compute			210011	0,700	34	57
Succession Electronics of Compare	(0.01/2)					0 ,
Energy Technology						
Glori Energy, Inc. (3)	Energy Technology	Equity	Common			
			Stock	18,208	165	39
SCIEnergy, Inc.	Energy Technology	Equity	Preferred			
						~ 4
			Series 1	385,000	761	24
Subtotal: Energy Technology (0.0	01%)*		Series 1	385,000	761 926	63
Subtotal: Energy Technology (0.0)1%)*		Series 1	385,000		
Subtotal: Energy Technology (0.0 Information Services	01%)*		Series 1	385,000		
	01%)* Information Services	Equity	Series 1 Common	385,000		
Information Services		Equity		385,000 500,000		
Information Services Good Technology Corporation	Information Services	Equity	Common		926	63
Information Services Good Technology Corporation (p.k.a. Visto Corporation) (13)	Information Services	Equity	Common		926	63
Information Services Good Technology Corporation (p.k.a. Visto Corporation) (13)	Information Services .08%)*	Equity	Common		926	63

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Blurb, Inc. (13)	Internet Consumer &	Equity	Preferred			
	Business Services		Series B	220,653	175	279
Lightspeed POS, Inc. (4)(9)	Internet Consumer &	Equity	Preferred			
	Business Services		Series C	23,003	250	274
Oportun (p.k.a. Progress	Internet Consumer &	Equity	Preferred			
Financial)	Business Services		Series G	218,351	250	402
	Internet Consumer &	Equity	Preferred			
	Business Services		Series H	87,802	250	252
Total Oportun (p.k.a. Progress Financial)				306,153	500	654
Philotic, Inc.	Internet Consumer &	Equity	Common			
	Business Services		Stock	9,023	93	
RazorGator Interactive Group,	Internet Consumer &	Equity	Preferred			
Inc.	Business Services		Series AA	34,783	15	30
Taptera, Inc.	Internet Consumer &	Equity	Preferred			
•	Business Services	• •	Series B	454,545	150	176
Subtotal: Internet Consumer & B	usiness Services					
(0.19%)*					1,183	1,413

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

_	١.		c
	V.	ne.	OT
	.y	Pυ	OI

Portfolio Company	Sub-Industry	Investment(1)	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Medical Devices & Equipa						
Flowonix Medical Incorporated	Medical Devices & Equipment	Equity	Preferred Series E	221,893	\$1,500	\$1,794
Gelesis, Inc. (5)(13)	Medical Devices & Equipment	Equity	Preferred Series A-1	674,208	425	785
	Medical Devices & Equipment	Equity	Preferred Series A-2	675,676	500	737
	Medical Devices & Equipment	Equity	Common Stock	698,862	_	714
Total Gelesis, Inc.	Equipment			2,048,746	925	2,236
Medrobotics Corporation (13)	Medical Devices & Equipment	Equity	Preferred Series E	136,798	250	162
,	Medical Devices & Equipment	Equity	Preferred Series F	73,971	155	173
Total Medrobotics Corpora	* *		Series r	210,769	405	335
Novasys Medical, Inc.	Medical Devices &	Equity	Preferred	210,709	403	333
·	Equipment		Series D-1	4,118,444	1,000	_
Optiscan Biomedical, Corp. (5)(13)	Medical Devices & Equipment	Equity	Preferred Series B	6,185,567	3,000	539
1	Medical Devices & Equipment	Equity	Preferred Series C	1,927,309	655	162
	Medical Devices & Equipment	Equity	Preferred Series D	55,103,923	5,257	5,789
Total Optiscan Biomedical			Selles D	63,216,799	8,912	6,490
Oraya Therapeutics, Inc.	Medical Devices & Equipment	Equity	Preferred Series 1	1,086,969	500	429
Subtotal: Medical Devices	1 1		Series 1	1,080,909	13,242	11,284
Subtotal: Medical Devices	& Equipment (1.48%)**				13,242	11,284
Software						
Atrenta, Inc.	Software	Equity	Preferred Series C	1,196,845	986	2,045
Atrenta, Inc.	Software	Equity	Preferred Series D	635,513	508	1,231
			SCIICS D	033,313	500	1,231

Total Atrenta, Inc.				1,832,358	1,494	3,276
Box, Inc. (3) (13)	Software	Equity	Common Stock	1,464,747	5,818	28,930
CapLinked, Inc.	Software	Equity	Preferred			
			Series A-3	53,614	51	81
ForeScout Technologies,	Software	Equity	Preferred			
Inc.			Series D	319,099	398	564
	Software	Equity	Preferred			
			Series E	80,587	131	146
Total ForeScout Technolog	9 .			399,686	529	710
HighRoads, Inc.	Software	Equity	Preferred			
40			Series B	190,170	307	343
WildTangent, Inc. (13)	Software	Equity	Preferred			
			Series 3	100,000	402	237
Subtotal: Software (4.40%))*				8,601	33,577
Specialty Pharmaceuticals	0 11	.	D C 1			
QuatRx Pharmaceuticals	Specialty	Equity	Preferred	241.020	750	
Company	Pharmaceuticals	.	Series E	241,829	750	_
	Specialty	Equity	Preferred	26.055		
	Pharmaceuticals	E ausitus	Series E-1 Preferred	26,955		_
	Specialty Pharmaceuticals	Equity	Series G	1 667 626		
Total Quathy Pharmacaut			Series G	4,667,636 4,936,420		
Total QuatRx Pharmaceuti Subtotal: Specialty Pharma				4,930,420	750	_
Subtotal. Specialty Filarina	aceuticais (0.00%).				730	_
Surgical Devices						
Gynesonics, Inc. (13)	Surgical Devices	Equity	Preferred			
Gynesomes, me.	Surgicui Devices	Equity	Series B	219,298	250	104
	Surgical Devices	Equity	Preferred	217,270	200	101
	Suigioni Bottoos	_quity	Series C	656,538	282	199
	Surgical Devices	Equity	Preferred	32 3,2 2 3		
		13	Series D	1,991,157	712	1,090
Total Gynesonics, Inc.				2,866,993	1,244	1,393
Transmedics, Inc.	Surgical Devices	Equity	Preferred	, ,	,	,
•	C	1 3	Series B	88,961	1,100	402
	Surgical Devices	Equity	Preferred			
	· ·		Series C	119,999	300	234
	Surgical Devices	Equity	Preferred			
			Series D	260,000	650	1,129
Total Transmedics, Inc.				468,960	2,050	1,765
Subtotal: Surgical Devices	(0.41%)*				3,294	3,158
Total: Equity Investments	(9.49%)*				44,188	72,451

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

Type of	
---------	--

Portfolio Company	Sub-Industry	Investment(1)	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Warrant Investments						
Biotechnology Tools						
Labcyte, Inc. (13)	Biotechnology Tools	Warrant	Preferred			
			Series C	1,127,624	\$323	\$ 425
Subtotal: Biotechnology Tools (0.	06%)*				323	425
Communications & Networking						
Intelepeer, Inc. (13)	Communications &	Warrant	Preferred			
	Networking		Series C	117,958	102	
OpenPeak, Inc.	Communications &	Warrant	Common			
	Networking		Stock	108,982	149	
PeerApp, Inc.	Communications &	Warrant	Preferred			
	Networking		Series B	298,779	61	68
Peerless Network, Inc.	Communications &	Warrant	Preferred			
	Networking		Series A	135,000	95	717
Ping Identity Corporation	Communications &	Warrant	Preferred			
	Networking		Series B	1,136,277	52	212
SkyCross, Inc. (13)	Communications &	Warrant	Preferred			
•	Networking		Series F	9,762,777	394	
Spring Mobile Solutions, Inc.	Communications &	Warrant	Preferred	,		
,	Networking		Series D	2,834,375	418	258
Subtotal: Communications & Netv				, ,	1,271	1,255
	8 (** **)				,	,
Consumer & Business Products						
Antenna79 (p.k.a. Pong Research	Consumer & Business	Warrant	Preferred			
Corporation) (13)	Products		Series A	1,662,441	228	36
Intelligent Beauty, Inc. (13)	Consumer & Business	Warrant	Preferred	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Products		Series B	190,234	230	284
IronPlanet, Inc.	Consumer & Business	Warrant	Preferred			
	Products		Series D	1,155,821	1,076	1,140
Market Force Information, Inc.	Consumer & Business	Warrant	Preferred	_,122,321	1,0.0	1,1.0
	Products	==-	Series A-1	150,212	24	8
	210000		~ - II - I			0

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

The Neat Company (13)	Consumer & Business	Warrant	Preferred			
	Products		Series C-1	540,540	366	356
Subtotal: Consumer & Business Pr	roducts (0.24%)*				1,924	1,824
Diagnostic						
Navidea Biopharmaceuticals, Inc.	Diagnostic	Warrant	Common			
(p.k.a. Neoprobe)) (3)(13)	Diagnostic	vv arrant	Stock	333,333	244	28
Subtotal: Diagnostic (0.00%)*			Stock	333,333	244	28
Subtotal. Diagnostic (0.00%)					2-1-1	20
Drug Delivery						
AcelRx Pharmaceuticals, Inc.	Drug Delivery	Warrant	Common			
(3)(9)(13)			Stock	176,730	786	209
Agile Therapeutics, Inc (3)	Drug Delivery	Warrant	Common			
			Stock	180,274	730	686
Alexza Pharmaceuticals, Inc. (3)	Drug Delivery	Warrant	Common			
			Stock	37,639	645	_
BIND Therapeutics, Inc. (3)(13)	Drug Delivery	Warrant	Common			
			Stock	152,586	488	71
BioQuiddity Incorporated	Drug Delivery	Warrant	Common			
	D D !!	***	Stock	459,183	1	1
Celator Pharmaceuticals, Inc. (3)	Drug Delivery	Warrant	Common	210 655	120	105
G 1 : G G G	D D !!	***	Stock	210,675	138	135
Celsion Corporation (3)	Drug Delivery	Warrant	Common	104 006	420	122
Dance Biopharm, Inc. (13)	Drug Delivery	Warrant	Stock Preferred	194,986	428	133
Dance Biopharm, Inc. (19)	Drug Delivery	warrant	Series A	97,701	74	149
Edge Therapeutics, Inc.	Drug Delivery	Warrant	Preferred	71,701	/	177
Eage Therapeuties, me.	Diag Delivery	vv arrant	Series C-1	107,526	390	258
Egalet Corporation (3)	Drug Delivery	Warrant	Common	107,820	270	200
-8		.,	Stock	113,421	130	735
Kaleo, Inc. (p.k.a. Intelliject, Inc.)	Drug Delivery	Warrant	Preferred	ĺ		
•			Series B	82,500	594	1,316
Neos Therapeutics, Inc. (13)	Drug Delivery	Warrant	Preferred			
			Series C	170,000	285	325
Revance Therapeutics, Inc. (3)	Drug Delivery	Warrant	Common			
			Stock	53,511	557	88
Zosano Pharma, Inc. (3)	Drug Delivery	Warrant	Common			
			Stock	31,674	164	99
Subtotal: Drug Delivery (0.55%)*					5,410	4,205

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

Type of

Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Drug Discovery & Developm	nent					
ADMA Biologics, Inc. (3)	Drug Discovery & Development	Warrant	Common Stock	89,750	\$295	\$ 278
Anthera Pharmaceuticals, Inc. (3)(13)	Drug Discovery & Development	Warrant	Common Stock	40,178	984	_
Aveo Pharmaceuticals, Inc. (3)(9)(13)	Drug Discovery & Development	Warrant	Common Stock	608,696	194	462
Cerecor Inc.	Drug Discovery & Development	Warrant	Preferred Series B	625,208	70	30
Cerulean Pharma Inc. (3)	Drug Discovery & Development	Warrant	Common Stock	137,521	357	569
Chroma Therapeutics, Ltd. (4)(9)	Drug Discovery & Development	Warrant	Preferred Series D	325,261	490	_
Cleveland BioLabs, Inc. (3)(13)	Drug Discovery & Development	Warrant	Common Stock	7,813	105	3
Concert Pharmaceuticals, Inc. (3)	Drug Discovery & Development	Warrant	Common Stock	70,796	367	198
Coronado Biosciences, Inc.	Drug Discovery & Development	Warrant	Common Stock	73,009	142	85
Dicerna Pharmaceuticals, Inc. (3)(13)	Drug Discovery & Development	Warrant	Common Stock	200	28	_
Epirus Biopharmaceuticals, Inc. (3)	Drug Discovery & Development	Warrant	Common Stock	64,194	276	353
Genocea Biosciences, Inc. (3)		Warrant	Common Stock	73,725	266	389
Horizon Pharma, Inc. (3)	Drug Discovery & Development	Warrant	Common Stock	3,735	52	27
Melinta Therapeutics	Drug Discovery & Development	Warrant	Preferred Series 3	1,151,936	603	548
Nanotherapeutics, Inc. (13)	Drug Discovery & Development	Warrant	Common Stock	171,389	838	1,488
Neothetics, Inc. (p.k.a. Lithera, Inc) (3)(13)	Drug Discovery & Development	Warrant	Common Stock	46,838	266	133
Neuralstem, Inc. (3)(13)	& Development	Warrant	Common Stock	75,187	77	44

	Drug Discovery & Development					
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept	•	Warrant	Common Stock			
Pharmaceuticals, Inc.) (3)	& Development			5,121	87	5
uniQure B.V. (3)(4)(9)	Drug Discovery & Development	Warrant	Common Stock	37,174	218	389
XOMA Corporation (3)(9)(13)	Drug Discovery	Warrant	Common Stock			
Subtotal: Drug Discovery &	& Development			181,268	279	272
(0.69%)*	Bevelopment				5,994	5,273
					·	
Electronics & Computer Har	dware					
Clustrix, Inc.	Electronics &	Warrant	Common Stock			
	Computer					
Subtatal Electronics & Com	Hardware Hardware			50,000	12	9
Subtotal: Electronics & Com (0.00%)*	puter Hardware				12	9
Energy Technology						
Agrivida, Inc. (13)	Energy	Warrant	Preferred Series D			
	Technology			471,327	120	203
Alphabet Energy, Inc. (13)	Energy	Warrant	Preferred Series A	06 220	0.1	101
American Superconductor	Technology Energy	Warrant	Common Stock	86,329	81	181
Corporation (3)	Technology	,, arraire	Common Stock	58,823	39	69
Brightsource Energy, Inc. (13)	Energy Technology	Warrant	Preferred Series 1	175,000	780	185
Calera, Inc. (13)	Energy Technology	Warrant	Preferred Series C	44,529	513	_
EcoMotors, Inc. (13)	Energy Technology	Warrant	Preferred Series B	437,500	308	314
Fluidic, Inc.	Energy Technology	Warrant	Preferred Series D	61,804	102	44
Fulcrum Bioenergy, Inc.	Energy	Warrant	Preferred Series C-1	01,001	102	
	Technology			280,897	274	186
GreatPoint Energy, Inc. (13)	Energy Technology	Warrant	Preferred Series D-1	393,212	548	_
Polyera Corporation (13)	Energy Technology	Warrant	Preferred Series C	311,609	337	534
SCIEnergy, Inc.	Energy Technology	Warrant	Common Stock	530,811	181	_
	Energy	Warrant	Preferred Series 1	,	_	
	Technology			145,811	50	_
Total SCIEnergy, Inc.	Energy	Woment	Drafamad Carias A 1	676,622	231	_
Scifiniti (p.k.a. Integrated Photovoltaics, Inc.) (13)	Energy Technology	Warrant	Preferred Series A-1	390,000	82	70
Solexel, Inc. (13)	Energy	Warrant	Preferred Series C	570,000	02	70
	Technology			1,171,625	1,162	673

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Stion Corporation (5)	Energy	Warrant	Preferred Series Seed			
	Technology			2,154	1,378	_
Sungevity Development,	Energy	Warrant	Preferred Series C			
LLC	Technology			32,472,222	903	903
TAS Energy, Inc.	Energy	Warrant	Preferred Series AA			
	Technology			428,571	299	
TPI Composites, Inc.	Energy	Warrant	Preferred Series B			
	Technology			160	273	201
Trilliant, Inc. (13)	Energy	Warrant	Preferred Series A			
	Technology			320,000	162	40
Subtotal: Energy Technolog	y (0.47%)*				7,592	3,603
Healthcare Services, Other						
Chromadex Corporation	Healthcare	Warrant	Common Stock			

419,020

156

156

200

200

See notes to consolidated financial statements.

Subtotal: Healthcare Services, Other (0.03%)*

Services, Other

18

(3)(13)

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

Tv	pe	of
)	~	-

Portfolio Company	Sub-Industry	Investment(1)	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Information Services						
Cha Cha Search, Inc. (13)	Information Services	Warrant	Preferred Series G	48,232	\$58	\$4
INMOBI Inc. (4)(9)	Information Services	Warrant	Common Stock	46,874	82	30
InXpo, Inc. (13)	Information Services	Warrant	Preferred Series C	648,400	98	14
	Information Services	Warrant	Preferred Series C-1	740,832	59	17
Total InXpo, Inc.				1,389,232	157	31
RichRelevance, Inc. (13)	Information Services	Warrant	Preferred Series E	112,612	98	_
Subtotal: Information Servi	ces (0.01%)*			•	395	65
Internet Consumer & Busin	ess Services					
Blurb, Inc. (13)	Internet Consumer & Business Services	Warrant	Preferred Series B	218,684	299	77
	Internet Consumer & Business Services	Warrant	Preferred Series C	234,280	636	183
Total Blurb, Inc.				452,964	935	260
CashStar, Inc. (13)	Internet Consumer & Business Services	Warrant	Preferred Series C-2	727,272	130	108
Gazelle, Inc. ⁽¹³⁾	Internet Consumer & Business Services	Warrant	Preferred Series A-1	991,288	158	85
Just Fabulous, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B	206,184	1,101	1,600
Lightspeed POS, Inc. (4)(9)	Internet Consumer & Business Services	Warrant	Preferred Series C	24,561	20	68
Oportun (p.k.a. Progress Financial)	Internet Consumer & Business Services	Warrant	Preferred Series G	174,562	78	155
Prism Education Group, Inc. (13)	Internet Consumer & Business Services	Warrant	Preferred Series B	200,000	43	
Reply! Inc.		Warrant		137,225	320	_

	Internet Consumer &		Preferred			
ShareThis, Inc. (13)	Business Services Internet Consumer &	Warrant	Series B Preferred			
Snare Inis, Inc. (13)	Business Services	w arrant	Series C	493,502	547	262
Tapjoy, Inc.	Internet Consumer &	Warrant	Preferred			
	Business Services		Series D	748,670	316	102
Tectura Corporation	Internet Consumer & Business Services	Warrant	Preferred Series B-1	253,378	51	_
Subtotal: Internet Consumer	r & Business Services					
(0.35%)*					3,699	2,640
M 1 10						
Media/Content/Info	Madia/Cantant/Infa	Wannant	Camman			
Rhapsody International, Inc. (13)	Media/Content/Info	Warrant	Common Stock	715,755	384	393
Zoom Media Group, Inc.	Media/Content/Info	Warrant	Preferred	713,733	304	393
Zoom wedia Group, me.	Wiedlay Contenty Info	vv arraint	Series A	1,204	348	262
Subtotal: Media/Content/Inf	fo (0.09%)*			_,	732	655
Medical Devices & Equipm			_			
Amedica Corporation (3) (13)		Warrant	Common	516 100	450	
Assadas Tas (13)	Equipment Medical Devices &	Wannant	Stock Preferred	516,129	459	-
Avedro, Inc. (13)	Equipment	Warrant	Series D	1,308,451	401	592
Aspire Bariatrics, Inc. (13)	Medical Devices &	Warrant	Preferred	1,300,431	401	392
rispire Bariatries, inc.	Equipment	vv arrain	Series D	335,000	419	426
Flowonix Medical	Medical Devices &	Warrant	Preferred	,		
Incorporated	Equipment		Series E	110,947	203	428
Gamma Medica, Inc.	Medical Devices &	Warrant	Preferred			
(5)(12)	Equipment		Series A	357,500	170	183
Gelesis, Inc. ⁽⁵⁾⁽¹³⁾	Medical Devices &	Warrant	Preferred	262.600	70	170
Hama Dialusia Dhua Ina	Equipment Medical Devices &	Wannant	Series A-1	263,688	78	178
Home Dialysis Plus, Inc.	Equipment	Warrant	Preferred Series A	500,000	402	585
InspireMD, Inc. (3)(4)(9)	Medical Devices &	Warrant	Common	300,000	402	363
mopriente, me.	Equipment	vv arraint	Stock	168,351	242	4
Medrobotics Corporation	Medical Devices &	Warrant	Preferred	7		
(13)	Equipment		Series E	455,539	370	213
MELA Sciences, Inc. (3)	Medical Devices &	Warrant	Common			
- (12)	Equipment		Stock	69,320	402	14
nContact Surgical, Inc (13)	Medical Devices &	Warrant	Preferred	201 422	066	(20
NotDia Ina	Equipment	Wannant	Series D-1	201,439	266	620
NetBio, Inc.	Medical Devices & Equipment	Warrant	Common Stock	2,568	408	56
NinePoint Medical, Inc. (13)		Warrant	Preferred	4,300	+00	50
Timer ome medicul, me.	Equipment Equipment	,, arrant	Series A-1	587,840	170	262
Novasys Medical, Inc.	Medical Devices &	Warrant	Common	.,		
•	Equipment		Stock	109,449	2	
	Medical Devices &	Warrant	Preferred			
	Equipment		Series D	526,840	125	_

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Medical Devices &	Warrant	Preferred			
	Equipment		Series D-1	53,607	6	
Total Novasys Medical, Inc	c.			689,896	133	_
Optiscan Biomedical, Corp	. Medical Devices &	Warrant	Preferred			
(5)(13)	Equipment		Series D	10,535,275	1,252	278
Oraya Therapeutics, Inc.	Medical Devices &	Warrant	Common			
	Equipment		Stock	954	66	_
	Medical Devices &	Warrant	Preferred			
	Equipment		Series 1	1,632,084	676	132
Total Oraya Therapeutics,	Inc.			1,633,038	742	132
Quanterix Corporation	Medical Devices &	Warrant	Preferred			
	Equipment		Series C	115,618	156	138
SonaCare Medical, LLC	Medical Devices &	Warrant	Preferred			
(p.k.a. US HIFU, LLC)	Equipment		Series A	6,464	188	_
ViewRay, Inc. (13)	Medical Devices &	Warrant	Preferred			
	Equipment		Series C	43,103	333	316
Subtotal: Medical Devices	& Equipment (0.58%)*				6,794	4,425

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Tv	ne	of
. J	PΨ	O1

Portfolio Company	Sub-Industry	Investment(1)	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Semiconductors						
Achronix Semiconductor	Semiconductors	Warrant	Preferred			
Corporation			Series C	360,000	\$160	\$ 23
Aquantia Corp.	Semiconductors	Warrant	Preferred			
			Series G	196,831	4	3
Avnera Corporation	Semiconductors	Warrant	Preferred			
			Series E	102,958	14	34
Subtotal: Semiconductors (0.01%)	*				178	60

Software

Software						
Atrenta, Inc.	Software	Warrant	Preferred Series D	392,670	120	432
Braxton Technologies, LLC	Software	Warrant	Preferred Series A	168,750	188	_
CareCloud Corporation (13)	Software	Warrant	Preferred Series B	413,433	258	452
Clickfox, Inc. (13)	Software	Warrant	Preferred Series B	1,038,563	330	990
	Software	Warrant	Preferred Series C	592,019	730	676
	Software	Warrant	Preferred Series C-A	46,109	13	44
Total Clickfox, Inc.				1,676,691	1,073	1,710
Daegis Inc. (p.k.a. Unify Corporation) (3) (13)	Software	Warrant	Common Stock	718,860	1,434	3
Hillcrest Laboratories, Inc. (13)	Software	Warrant	Preferred Series E	1,865,650	55	123
JumpStart Games, Inc. (p.k.a. Knowledge Holdings, Inc.) (13)	Software	Warrant	Preferred Series E	614,333	16	8
Message Systems, Inc. (13)	Software	Warrant	Preferred Series B	408,011	334	330
Mobile Posse, Inc. (13)	Software	Warrant	Preferred Series C	396,430	130	58

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Neos Geosolutions, Inc. (13)	Software	Warrant	Preferred Series 3	221,150	22	_
NewVoiceMedia Limited (4)(9)	Software	Warrant	Preferred	,		
			Series E	225,586	33	71
Poplicus Incorporated (13)	Software	Warrant	Preferred			
			Series B-1	2,595,230	_	87
Soasta, Inc. (13)	Software	Warrant	Preferred			
			Series E	410,800	691	717
Sonian, Inc. (13)	Software	Warrant	Preferred			
			Series C	185,949	106	65
StrongView Systems, Inc.	Software	Warrant	Preferred			
			Series C	551,470	168	227
SugarSync, Inc. (13)	Software	Warrant	Preferred			
			Series CC	332,726	78	102
	Software	Warrant	Preferred			
			Series DD	107,526	34	34
Total SugarSync, Inc.				440,252	112	136
Touchcommerce, Inc. (13)	Software	Warrant	Preferred			
11.50			Series E	1,885,930	361	282
White Sky, Inc. (13)	Software	Warrant	Preferred			
			Series B-2	124,295	54	6
Subtotal: Software (0.62%)*					5,155	4,707
Specialty Pharmaceuticals						
Alimera Sciences, Inc. (3)	Specialty	Warrant	Common			
	Pharmaceuticals		Stock	285,016	729	521
QuatRx Pharmaceuticals Company	•	Warrant	Preferred			
	Pharmaceuticals		Series E	155,324	307	
Subtotal: Specialty Pharmaceuticals	s (0.17%)*				1,036	521

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2015

(unaudited)

(dollars in thousands)

Type of

Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾		
Surgical Devices								
Gynesonics, Inc. (13)	Surgical Devices	Warrant	Preferred Series C	180,480	\$75	\$50		
	Surgical Devices	Warrant	Preferred Series D	1,575,965	320	585		
Total Gynesonics, Inc	c.			1,756,445	395	635		
Transmedics, Inc.	Surgical Devices	Warrant	Preferred Series B	40,436	224	4		
	Surgical Devices	Warrant	Preferred Series D	175,000	100	404		
Total Transmedics, In	nc.			215,436	324	408		
Subtotal: Surgical De	evices (0.14%)*				719	1,043		
Total Warrant Invest	Total Warrant Investments (4.05%)* 41,634 30,938							
Total Investments (13	52.15%)*				\$1,170,808	\$1,161,421		

^{*}Value as a percent of net assets

- (1) Preferred and common stock, warrants, and equity interests are generally non-income producing.
- (2) Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled \$50.4 million, \$60.9 million and \$10.5 million respectively. The tax cost of investments is \$1.2 billion.
- (3) Except for warrants in 33 publicly traded companies and common stock in 14 publicly traded companies, all investments are restricted at March 31, 2015 and were valued at fair value as determined in good faith by the Audit Committee of the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
- (4) Non-U.S. company or the company's principal place of business is outside the United States.
- (5) Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 5% but not more than 25% of the voting securities of the company.
- (6) Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 25% of the voting securities of the company or has greater than 50% representation on its board. There were no control investments at March 31, 2015.
- (7) Debt is on non-accrual status at March 31, 2015, and is therefore considered non-income producing.
- (8) Denotes that all or a portion of the debt investment is convertible senior debt.
- (9) Indicates assets that the Company deems not "qualifying assets" under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company's total assets at the time of acquisition of any additional non-qualifying assets.
- (10) Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitizations (as defined in Note 4).

(11)

Denotes that all or a portion of the debt investment principal includes accumulated PIK, or payment-in-kind, interest and is net of repayments.

- (12) Denotes that all or a portion of the debt investment includes an exit fee receivable.
- (13)Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company's wholly-owned SBIC subsidiaries.
- (14) The stated 'Maturity Date' for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company's investment team and Investment Committee continue to closely monitor developments at the borrower company.

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of			Principal		
folio		T (1)	M. C. D.	T. D. IEI		G (2)	X 7 1
npany t Investme	•	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	Cost(2)	Value
echnology							
Years Ma	•						
	•	Senior Secured	June 2016	Interest rate PRIME + 6.70%			
				or Floor rate of 9.95%	\$2,695	\$2,869	\$2,86
	Years Maturity					2,869	2,86
total: Biot	technology Tools (0.44%)*					2,869	2,86
nmunicati	ions & Networking						
Years Ma							
nPeak, (10)(12)	Communications & Networking	Senior Secured	April 2017	Interest rate PRIME + 8.75%			
				or Floor rate of 12.00%	\$12,889	13,193	13,1
Cross, (12)(13)	Communications & Networking	Senior Secured	January 2018	Interest rate PRIME + 9.70%			
1				or Floor rate of 12.95%	\$22,000	21,580	20,1
ng oile	Communications & Networking	Senior Secured	November 2016	Interest rate PRIME + 8.00%			
itions,				or Floor rate of 11.25%			
(10)(12)					\$18,840	18,928	19,1
	Years Maturity					53,701	52,4
total: Com 6%)*	mmunications & Networking					53,701	52,4
sumer & !	Business Products						
Years Ma	•						
enna79 .a. Pong	Consumer & Business Products	Senior Secured	December 2017				
earch poration)				or Floor rate of 10.00%			
13)					\$5,000	4,912	4,88
	Consumer & Business Products	Senior Secured	June 2016	Interest rate PRIME + 6.75%	\$216	89	89

				or Floor rate of 10.00%			
ıl Antenna	a79 (p.k.a. Pong Research						1
poration)					\$5,216	5,001	4,97
, Inc. ⁽⁸⁾	Consumer & Business Products		March 2017	Interest rate FIXED 4.00%			100
		Senior Note			\$100	100	100
Planet,	Consumer & Business Products	Senior Secured	November 2017	Interest rate PRIME + 6.20%			
				or Floor rate of 9.45%	\$37,500	36,345	36,3
Neat npany	Consumer & Business Products	Senior Secured	September 2017	Interest rate PRIME + 7.75%			
12)(13)				or Floor rate of 11.00%,			
				PIK Interest 1.00%	\$20,061	19,422	19,4
total: 1-5 `	Years Maturity					60,868	60,8
total: Cons	sumer & Business Products						
3%)*						60,868	60,8

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

•	Type of		T. D. I	Principal			
Portfolio Company	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Drug Delivery							
Under 1 Year Mat	urity						
Revance	Drug	Senior	March 2015	Interest rate PRIME			
Therapeutics, Inc. (10)(12)	Delivery	Secured		+ 6.60%			
				or			
	Б	G :	N. 1.0015	Floor rate of 9.85%	\$2,098	\$2,458	\$2,458
	Drug Delivery	Senior Secured	March 2015	Interest rate PRIME + 6.60%			
				or			
				Floor rate of 9.85%	\$210	246	246
Total Revance The	erapeutics,						
Inc.					\$2,308	2,704	2,704
Subtotal: Under 1 Maturity	Year					2,704	2,704
1-5 Years Maturity	y						
AcelRx	Drug	Senior	October 2017	Interest rate PRIME			
Pharmaceuticals, Inc. (9)(10)(12)(13)	Delivery	Secured		+ 3.85%			
				or Floor rate of			
				9.10%	\$25,000	24,831	24,969
BIND Therapeutics, Inc. (12)(13)	Drug Delivery	Senior Secured	September 2016	Interest rate PRIME + 7.00%			
				or			
				Floor rate of 10.25%	\$3,274	3,343	3,228
BioQuiddity Incorporated (12)	Drug Delivery	Senior Secured	May 2018	Interest rate PRIME + 8.00%			
				or			
				Floor rate of 11.25%	\$7,500	7,439	7,439
Celator Pharmaceuticals,	Drug Delivery	Senior Secured	June 2018	Interest rate PRIME + 6.50%	\$10,000	9,927	9,899

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Inc. (10)(12)				or			
Celsion Corporation (10)(12)	Drug Delivery	Senior Secured	June 2017	Floor rate of 9.75% Interest rate PRIME + 8.00%			
				or Floor rate of 11.25%	\$10,000	9,858	10,027
Dance Biopharm, Inc. (12)(13)	Drug Delivery	Senior Secured	November 2017	Interest rate PRIME + 7.40%			
				or	¢ 2 005	2 071	2 061
Edge Therapeutics, Inc. (12)	Drug Delivery	Senior Secured	March 2018	Floor rate of 10.65% Interest rate PRIME + 5.95%	\$ 3,903	3,871	3,864
				or Floor rate of 10.45%	\$3,000	2,847	2,847
Neos Therapeutics, Inc. (12)(13)	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 7.25%			
				or Floor rate of 10.50%	\$5,000	4,916	4,916
	Drug	Senior	October 2017	Interest rate FIXED	,	,	
Total Neos Therap	Delivery	Secured		9.00%	\$10,000 \$15,000	10,010 14,926	10,063 14,979
Zosano Pharma, Inc. (10)(12)	Drug Delivery	Senior Secured	June 2017	Interest rate PRIME + 6.80%	\$ 13,000	14,920	14,979
				or			
Subtotal: 1-5 Year	re Maturity			Floor rate of 12.05%	\$4,000	3,894 80,936	3,881 81,133
Subtotal: 1-3 Tear	•					00,930	01,133
(12.72%)*	· 32 J					83,640	83,837

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of			Principal	
mpany	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾
ery & Developm	nent					
r Maturity						
aceuticals, (13)	Drug Discovery & Development	Senior Secured	December 2015	Interest rate PRIME + 7.15%		
				or Floor rate of 11.90%	\$11,611	\$11,611
maceuticals,	Drug Discovery & Development	Senior Secured	October 2015	Interest rate PRIME + 3.25%		
				or Floor rate of 8.50%	\$7,175	7,142
der 1 Year Matu aturity	rity					18,753
ogics,	Drug Discovery & Development	Senior Secured	December 2017	Interest rate PRIME + 5.5%		
				or Floor rate of 8.75%,		
				PIK Interest 1.95%	\$5,000	4,879
	Drug Discovery & Development	Senior Secured	December 2017		Ψυ,	.,0.2
				or Floor rate of 8.75%,		
				PIK Interest 1.95%	\$10,153	10,032
Biologics, Inc.					\$15,153	14,911
	Drug Discovery & Development	Senior Secured	January 2018	Interest rate PRIME + 6.65%		
				or Floor rate of 11.90%	\$10,000	9,766
rporation (12)(13)	Drug Discovery & Development	Senior Secured	February 2018	Interest rate PRIME + 5.00%		
				or Floor rate of 8.25%	\$10,000	10,022
(10)(12)	Drug Discovery & Development	Senior Secured	April 2018	Interest rate PRIME + 6.30%		
				or Floor rate of 9.55%	\$18,000	18,020
(12)	Drug Discovery & Development	Senior Secured	August 2017	Interest rate PRIME + 6.30%		
				or Floor rate of 9.55%	\$7,500	7,374
oLabs,	Drug Discovery & Development	Senior Secured	January 2017	Interest rate PRIME + 6.10%		
				or Floor rate of 9.35%	\$1,883	1,883

Drug Discovery & Development S	Senior Secured	October 2016	Interest rate PRIME + 6.75%	÷ . 50.4	1.704
				\$4,584	4,584
Drug Discovery & Development S	Senior Secured	October 2016	Interest rate PRIME + 9.00%		
			or Floor rate of 12.25%	\$13,890	13,890
(pka Cell Therapeutics, Inc.)				\$18,474	18,474
Drug Discovery & Development S	Senior Secured	July 2018	Interest rate PRIME + 6.50%		
			or Floor rate of 9.75%	\$10,000	9,897
Drug Discovery & Development S	Senior Secured	April 2018	Interest rate PRIME + 4.70%		
			or Floor rate of 7.95%	\$7,500	7,308
Drug Discovery & Development	Senior Secured	July 2018	Interest rate PRIME + 2.25%		
			or Floor rate of 7.25%	\$12,000	11,814
Drug Discovery & Development S	Senior Secured	January 2018	Interest rate PRIME + 4.75%		
			or Floor rate of 9.25%	\$25,000	24,854
Drug Discovery & Development S	Senior Secured	June 2018	Interest rate PRIME + 5.00%		
			or Floor rate of 8.25%	\$20,000	19,272
Drug Discovery & Development S	Senior Secured	November 2016			
			or Floor rate of 10.55%	\$40,000	40,578
Drug Discovery & Development S	Senior Secured	January 2018	Interest rate PRIME + 5.75%		
				\$10,000	9,751
Drug Discovery & Development S	Senior Secured	April 2017	Interest rate PRIME + 6.75%	20.400	0.000
	2 . 2 . 1	2010		\$9,489	9,333
Drug Discovery & Development	Senior Secured			* : 7 000	
				\$15,000	14,890
Drug Discovery & Development S	Senior Secured	June 2018			
			or Floor rate of 10.25%	•	4,962
				\$20,000	19,852
					233,109
Development (38.41%)*					251,862
	Drug Discovery & Development (Page 1988) Drug Discovery & Development (Page 1988)	Drug Discovery & Development Senior Secured pka Cell Therapeutics, Inc.) Drug Discovery & Development Senior Secured Drug Discovery & Development Senior Secured	Drug Discovery & Development Senior Secured July 2018 Drug Discovery & Development Senior Secured April 2018 Drug Discovery & Development Senior Secured July 2018 Drug Discovery & Development Senior Secured January 2018 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured November 2016 Drug Discovery & Development Senior Secured January 2018 Drug Discovery & Development Senior Secured April 2017 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured June 2018	Or Floor rate of 10.00% Interest rate PRIME + 9.00% or Floor rate of 12.25% pka Cell Therapeutics, Inc.) Drug Discovery & Development Senior Secured July 2018 Drug Discovery & Development Senior Secured April 2018 Drug Discovery & Development Senior Secured July 2018 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured November 2016 Drug Discovery & Development Senior Secured June 2018 Drug Discovery & Development Senior Secured January 2018 Drug Discovery & Development Senior Secured June 20	or Floor rate of 10.00% \$4,584 Interest rate PRIME + 9.00% \$13,890 pka Cell Therapeutics, Inc.) \$18,474 Drug Discovery & Development Senior Secured July 2018 Interest rate PRIME + 6.50% or Floor rate of 9.75% \$10,000 Interest rate PRIME + 4.70% or Floor rate of 7.95% \$7,500 Interest rate PRIME + 2.25% or Floor rate of 7.25% \$12,000 Drug Discovery & Development Senior Secured July 2018 Interest rate PRIME + 2.25% or Floor rate of 7.25% \$12,000 Interest rate PRIME + 4.75% or Floor rate of 7.25% \$12,000 Interest rate PRIME + 4.75% or Floor rate of 9.25% \$25,000 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.00% or Floor rate of 8.25% \$20,000 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.30% or Floor rate of 10.55% \$40,000 Drug Discovery & Development Senior Secured April 2017 Interest rate PRIME + 5.75% or Floor rate of 10.00% \$10,000 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.00% or Floor rate of 10.00% \$9,489 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.25% or Floor rate of 10.25% \$15,000 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.25% or Floor rate of 10.25% \$5,000 Enterest rate PRIME + 5.25% \$15,000 Drug Discovery & Development Senior Secured June 2018 Interest rate PRIME + 5.25% or Floor rate of 10.25% \$5,000 Enterest rate PRIME + 5.25% \$5,000 Enterest rate

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of			Principal		
Portfolio Company	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Electronics & Comp	outer						
Hardware							
1-5 Years Maturity							
Plures	Electronics	Senior Secured	October 2016	Interest rate LIBOR + 8.75%			
Technologies, Inc. (7)(11)	& Computer Hardware			or Floor rate of 12.00%,			
me. V	Traidware			PIK Interest 4.00%	\$267	\$180	\$ —
Subtotal: 1-5 Years	Maturity					180	_
Subtotal: Electronic	_					100	
Hardware (0.00%)*						180	_
Energy Technology							
Under 1 Year Matur	itv						
Glori Energy, Inc.	Energy	Senior Secured	June 2015	Interest rate PRIME +			
(10)(12)	Technology			6.75%			
	_			or Floor rate of 10.00%	\$1,778	2,042	2,042
Scifiniti (pka	Energy	Senior Secured	February 2015	Interest rate PRIME +			
Integrated Photovoltaics, Inc.)	Technology			7.38%			
(13)				or Floor rate of 10.63%	\$227	227	227
Stion Corporation	Energy	Senior Secured	February 2015	Interest rate PRIME +	Ψ == /	,	,
(5)(12)	Technology		Ž	8.75%			
				or Floor rate of 12.00%	\$2,954	2,993	1,600
TAS Energy, Inc.	Energy	Senior Secured	December 2015	Interest rate PRIME +			
(10)(12)	Technology			7.75%			
				or Floor rate of 11.00%	\$6,901	7,091	7,091
Subtotal: Under 1 Y	ear Maturity			01 1 1001 tate 01 11.00 %	ψ0,701	12,353	10,960
1-5 Years Maturity						,	- ,
Agrivida, Inc.	Energy	Senior Secured	December 2016	Interest rate PRIME +	\$4,921	5,013	4,923
(12)(13)	Technology			6.75%			

				on Floor rate of 10,000/			
American	Energy	Senior Secured	March 2017	or Floor rate of 10.00% Interest rate PRIME +			
Superconductor Corporation (10)(12)	Technology	Semor Secured	111arch 2017	7.75%			
Corporation				or Floor rate of 11.00%	\$1,500	1,446	1,446
	Energy Technology	Senior Secured	November 2016	Interest rate PRIME + 7.25%			
				or Floor rate of 11.00%	\$7,667	7,847	7,847
Total American Sup Corporation	perconductor				\$9,167	9,293	9,293
Amyris, Inc. (9)(12)	Energy Technology	Senior Secured	February 2017	Interest rate PRIME + 6.25%			
				or Floor rate of 9.50%	\$25,000	25,000	25,170
	Energy Technology	Senior Secured	February 2017	Interest rate PRIME + 5.25%			
				or Floor rate of 8.50%	\$5,000	5,000	5,034
Total Amyris, Inc.		a : a . 1	1.0016	Y DDH (E	\$30,000	30,000	30,204
Fluidic, Inc. (10)(12)	Energy Technology	Senior Secured	March 2016	Interest rate PRIME + 8.00%			
	_			or Floor rate of 11.25%	\$3,674	3,747	3,721
Modumetal, Inc. (12)	Energy Technology	Senior Secured	March 2017	Interest rate PRIME + 8.70%			
				or Floor rate of 11.95%	\$3,000	2,991	2,991
Polyera Corporation (12)(13)	Energy Technology	Senior Secured	June 2016	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$3,654	3,818	3,810
Subtotal: 1-5 Years						54,862	54,942
Subtotal: Energy Te (10.00%)*	echnology					67,215	65,902
Healthcare Services	, Other						
1-5 Years Maturity Chromadex	Healthcare	Senior Secured	April 2018	Interest rate PRIME +			
Corporation (12)(13)	Services, Other	Semor Secured	71pm 2010	4.70%			
				or Floor rate of 7.95%	\$2,500	2,407	2,407
InstaMed Communications, LLC (13)	Healthcare Services, Other	Senior Secured	March 2018	Interest rate PRIME + 6.75%			
				or Floor rate of 10.00%	\$5,000	5,041	5,041
MDEverywhere, Inc. (10)(12)	Healthcare Services, Other	Senior Secured	January 2018	Interest rate LIBOR + 9.50%			
				or Floor rate of 10.75%	\$3,000	2,962	2,962

Subtotal: 1-5 Years Maturity	10,410	10,410
Subtotal: Healthcare Services,		
Other (1.58%)*	10,410	10,410

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

Doutfall:		Type of			Principal		
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Information S							
Under 1 Year	Maturity						
Eccentex	Information	Senior Secured	May 2015	Interest rate PRIME +			
Corporation	Services			7.00%			
(10)(12)				TI (10.056)	Φ20.4	Φ210	0.10.4
Subtotal: Und	lar 1 Vaar			or Floor rate of 10.25%	\$204	\$218	\$184
Maturity	iei i i eai					218	184
1-5 Years Ma	turity					210	104
INMOBI Inc.	×	Senior Secured	December 2016	Interest rate PRIME +			
(4)(9)(11)(12)	Services			7.00%			
				or Floor rate of 10.25%	\$9,612	9,283	9,283
	Information	Senior Secured	December 2017	Interest rate PRIME +			
	Services			5.75%			
				or Floor rate of 9.00%,			
				of 14001 fate of 9.00%,			
				PIK Interest 2.50%	\$15,013	14,820	14,820
Total INMOE	BI Inc.				\$24,625	24,103	24,103
InXpo, Inc.	Information	Senior Secured	July 2016	Interest rate PRIME +			
(12)(13)	Services			7.75%			
0.14 4.1.1.5	X 7			or Floor rate of 10.75%	\$2,057	2,073	1,976
Subtotal: 1-5 Maturity	Years					26,176	26.070
Subtotal: Info	ormation					20,170	26,079
Services (3.99						26,394	26,263
(5.15.						- ,	-,
Internet Cons							
Business Serv							
Under 1 Year	· · · · · · · · · · · · · · · · · · ·	a : a 1	D 1 0015	I DDIME	Ф1 001	1 021	1 021
Gazelle, Inc. (11)(13)		Senior Secured	December 2015	Interest rate PRIME +	\$1,231	1,231	1,231
(11)(10)	Consumer & Business			6.50%			
	Dusiness						

	Services			or Floor rate of 9.75%			
NetPlenish	Internet	Convertible	April 2015	Interest rate FIXED 10.00%			
(7)(8)(13)	Consumer &	Senior Note					
	Business				400	0.0	
	Services	a : a 1	g 1 2015	T	\$89	89	_
	Internet	Senior Secured	September 2015	Interest rate FIXED 10.00%			
	Consumer & Business						
	Services				\$381	373	
Total NetPlen					\$470	462	
Reply! Inc.	Internet	Senior Secured	September 2015	Interest rate PRIME +	ΨΤΙΟ	702	
(10)(11)(12)	Consumer &			6.88%			
	Business						
	Services			or Floor rate of 10.13%,			
				PIK Interest 2.00%	\$7,615	7,757	4,322
	Internet	Senior Secured	September 2015	Interest rate PRIME +			
	Consumer &			7.25%			
	Business			an Elean note of 11 000/			
	Services			or Floor rate of 11.00%,			
				PIK Interest 2.00%	\$1,680	1,749	955
Total Reply!	Inc.			THE Interest 2.00 /6	\$9,295	9,506	5,277
Tectura	Internet	Senior Secured	May 2014	Interest rate LIBOR +	7 - 7	- , -	,
Corporation	Consumer &		,	10.00%			
(7)(11)(15)	Business						
	Services			or Floor rate of 13.00%	\$563	563	121
	Internet	Senior Secured	May 2014	Interest rate LIBOR + 8.00%			
	Consumer &						
	Business			or Floor rate of 11.00%,			
	Services			PIK Interest 1.00%	\$9,070	0.070	1 511
	Internet	Senior Secured	May 2014	Interest rate LIBOR +	\$9,070	9,070	1,511
	Consumer &	Schol Secured	Way 2014	10.00%			
	Business			10.00%			
	Services			or Floor rate of 13.00%	\$5,000	5,000	1,074
	Internet	Senior Secured	May 2014	Interest rate LIBOR +			
	Consumer &			10.00%			
	Business						
m . 1 m .	Services			or Floor rate of 13.00%	\$6,468	6,468	1,390
Total Tectura	•				\$21,101	21,101	4,096
Subtotal: Und Maturity	ier i rear					32,300	10,604
1-5 Years Ma	turity					32,300	10,004
Education	Internet	Senior Secured	March 2016	Interest rate LIBOR + 12.5%			
Dynamics,	Consumer &						
LLC (11)(13)	Business			or Floor rate of 12.50%,			
	Services						
				PIK Interest 1.50%	\$20,563	20,546	20,559
Gazelle, Inc.	Internet	Senior Secured	July 2017	Interest rate PRIME + 7.00%	\$13,712	13,498	13,498
(11)(13)	Consumer &			or Floor rate of 10.25%,			

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

	Business			PIK Interest 2.50%			
	Services			TIK Interest 2.50 %			
Just	Internet	Senior Secured	February 2017	Interest rate PRIME +			
Fabulous,	Consumer &			8.25%			
Inc. (10)(12)	Business						
	Services			or Floor rate of 11.50%	\$15,000	14,468	14,768
Lightspeed	Internet	Senior Secured	May 2018	Interest rate PRIME +			
POS, Inc. (4)(9)(10)	Consumer &			3.25%			
(4)(9)(10)	Business Services			or Floor rate of 6.50%	\$2,000	1 005	1.004
Danlyd Inc		Canian Casumad	Eahmany 2016	Interest rate PRIME +	\$2,000	1,985	1,994
Reply! Inc. (10)(11)(12)	Internet Consumer &	Senior Secured	redruary 2010	7.25%			
]	Business			1.23 /0			
	Services			or Floor rate of 10.50%,			
	Ser vices			of 1 1001 face of 10.50 %,			
				PIK Interest 2.00%	\$2,721	2,658	1,548
Tapjoy, Inc.	Internet	Senior Secured	July 2018	Interest rate PRIME +			
(12)	Consumer &			6.50%			
	Business						
	Services			or Floor rate of 9.75%	\$3,000	2,921	2,921
WaveMarket,		Senior Secured	March 2017	Interest rate PRIME +			
Inc. (12)	Consumer &			6.50%			
	Business						
	Services			or Floor rate of 9.75%	\$300	303	303
Subtotal: 1-5 Years						55 501	
Maturity 56,379 55,591 Subtotal: Internet Consumer & Business Services (10.05%)* 88,679 66,195							
Subtotal: Inte	rnet Consume	r & Business Ser	vices (10.05%)*			88,679	66,195

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of			Principal		
Company	Sub-Industry	Investment(1)	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	V
ontent/Info							
Year Maturity							
edia Group,	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 7.25%			
				or Floor rate of 10.50%,			
				PIK Interest 3.75%	\$2,510	\$2,466	\$2
	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 5.25%			
				or Floor rate of 8.50%	\$5,060	5,002	5
om Media Gr	oup, Inc.				\$7,570	7,468	7
: Under 1 Yea	r Maturity					7,468	7
s Maturity	·						
y onal, 11)(13)	Media/Content/Info	Senior Secured	April 2018	Interest rate PRIME + 5.25%			
				or Floor rate of 9.00%,			
				PIK interest of 1.50%	\$20,206	19,750	j
: 1-5 Years M	aturity					19,750	J
: Media/Conte	ent/Info (4.11%)*					27,218	2
Devices & Eq	quipment						
Year Maturity							
Surgical, Inc.	Medical Devices & Equipment	Senior Secured	February 2015	Interest rate FIXED 12.50%	\$100	86	{
ialysis Plus,	Medical Devices & Equipment	Senior Secured	September 2015	Interest rate FIXED 8.00%	\$500	500	4
herapeutics,	Medical Devices & Equipment	Senior Secured	September 2015	Interest rate PRIME + 5.50% or Floor rate of 10.25%,			
				PIK Interest 1.00%	\$6,174	6,146	6
: Under 1 Yea	r Maturity					6,732	(

rs Maturity						
taion (8)(12)(13)	Medical Devices & Equipment S	Senior Secured	January 2018	Interest rate PRIME + 7.70%		
				or Floor rate of 10.95%	\$20,000	19,704
Inc. (12)(13)	Medical Devices & Equipment S	Senior Secured	December 2017	Interest rate PRIME + 8.25%		
				or Floor rate of 11.50%	\$7,500	7,247
Surgical, Inc.	Medical Devices & Equipment S	Senior Secured	March 2017	Interest rate PRIME + 7.75%		
				or Floor rate of 12.50%	\$7,113	7,040
x Medical ated ⁽¹²⁾	Medical Devices & Equipment S	Senior Secured	May 2018	Interest rate PRIME + 5.25%		
				or Floor rate of 10.00%	\$15,000	14,675
Medica, Inc.	Medical Devices & Equipment S	Senior Secured	January 2018	Interest rate PRIME + 6.50%		
				or Floor rate of 9.75%	\$4,000	3,874
ialysis Plus,	Medical Devices & Equipment S	Senior Secured	October 2017	Interest rate PRIME + 6.35%		
				or Floor rate of 9.60%	\$15,000	14,780
ID, Inc.	Medical Devices & Equipment 3	Senior Secured	February 2017	Interest rate PRIME +7.25%		
				or Floor rate of 10.50%	\$8,818	8,897
otics tion ⁽¹²⁾⁽¹³⁾	Medical Devices & Equipment S	Senior Secured	March 2016	Interest rate PRIME + 7.85%		
				or Floor rate of 11.10%	\$2,680	2,765
t Surgical,	Medical Devices & Equipment S	Senior Secured	November 2018	Interest rate PRIME + 9.25%		
				or Floor rate of 9.25%	\$10,000	9,735
Inc. ⁽¹⁰⁾	Medical Devices & Equipment S	Senior Secured	August 2017	Interest rate PRIME + 5.00%		
				or Floor rate of 11.00%	\$4,870	4,669
nt Medical,	Medical Devices & Equipment S	Senior Secured	January 2016	Interest rate PRIME + 5.85%		
	W # 15 1 65 1	a . a	N. 1 2027	or Floor rate of 9.10%	\$3,241	3,357
x tion ⁽¹⁰⁾⁽¹²⁾	Medical Devices & Equipment S	Senior Secured	November 2017	Interest rate PRIME + 2.75%		
3.6 31 3	W 1 1 D 1 2 D 1	g · g ·	1 2016	or Floor rate of 8.00%	\$5,000	4,930
e Medical, a US HIFU,	Medical Devices & Equipment S	Senior Secured	April 2016	Interest rate PRIME + 7.75%	\$875	1,200 1

			or Floor rate of 11.00%			
yes, Inc.	Medical Devices & Equipment Senior Secured Jan	nuary 2018	Interest rate PRIME + 7.75%			
			or Floor rate of 11.00%	\$5,000	5,034	2
y, Inc. (11)(13)	Medical Devices & Equipment Senior Secured Jun		Interest rate PRIME + 7.00%			
			or Floor rate of 10.25%,			
			PIK Interest 1.50%	\$15,220	14,920	1
: 1-5 Years M	aturity				122,827	1
: Medical Dev	vices & Equipment (19.23%)*				129,559	1

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

Double 1: a		Type of		Interest Data and	Principal		
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
•	·		•				
Semiconductors							
Under 1 Year Ma	aturity						
Achronix Semiconductor Corporation	<u> </u>	Senior Secured	January 2015	Interest rate PRIME + 10.60%			
				or			
0.11.11.1	137 36			Floor rate of 13.85%	\$95	\$95	\$95
Subtotal: Under 11-5 Years Maturi	· ·					95	95
Avnera Corporation (10)(12)	•	Senior Secured	April 2017	Interest rate PRIME + 5.75%			
				or			
				Floor rate of 9.00%	\$5,000	4,983	4,990
Subtotal: 1-5 Year	The state of the s					4,983	4,990
Subtotal: Semico	nductors					5 0 5 0	5 00 5
(0.77%)*						5,078	5,085
Software							
Under 1 Year Ma	aturity						
CareCloud Corporation	Software	Senior Secured	July 2015	Interest rate PRIME + 1.40%			
				or			
				Floor rate of 4.65%	\$3,000	2,968	2,968
Clickfox, Inc. (12)(13)	Software	Senior Secured	July 2015	Interest rate PRIME + 6.75%			
				or			
				Floor rate of 10.00%	\$2,000	2,000	2,000
Mobile Posse, Inc. (12)(13)	Software	Senior Secured	June 2015	Interest rate PRIME + 2.00%	\$1,000	993	988

Touchcommerce, Software Inc. (12X13) Touchcommerce, Software Inc. (12X13) Subtotal: Under 1 Year Maturity 1-5 Years Maturity CareCloud Software Corporation (12X13) Software Senior Secured July 2017 Software Senior Secured January 2018 Total CareCloud Corporation Clickfox, Inc. (12X13) Software Senior Secured December 2017 Total CareCloud Corporation Clickfox, Inc. (12X13) Software Senior Secured December 2017 Software Senior Secured March 2018 Senior Secured March 2018 Senior Secured March 2018 Senior Secured March 2018 Senior Secured October 2016 Interest rate PRIME + 8.25% or Floor rate of 11.50% \$13,208 \$12,972 \$11,750 \$11,771 \$11,709 \$11,700 \$11,771 \$11,709 Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) (QX(3) Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) (DX(3) Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) Mobile Posse, Software Senior Secured December 2016 Software Software Senior Secured December 2016 Software Software Senior Secured December 2016 Interest rate PRIME + 8.25% or Floor rate of 11.50% \$1,1,750 \$1,1,750 \$1,1,771 \$1,709 \$1,300 \$1,301								
Touchcommerce, Software Senior Secured January 2015 Interest rate PRIME + 2,25%					or Floor rate of 5.25%			
Subtotal: Under Year Maturity 1-5 Years Matur		, Software	Senior Secured	January 2015	Interest rate PRIME			
Subtotal: Under Year Maturity					or			
1-5 Years Maturity CareCloud Software Corporation (12)(13)					Floor rate of 6.50%	\$3,811	3,811	3,805
CareCloud Corporation (12)(3) Software Corporation (12)(3) Software Senior Secured December 2017 Interest rate PRIME + 3.25% Software Senior Secured July 2017 Interest rate PRIME + 5.50% Software Senior Secured July 2017 Interest rate PRIME + 5.50% Software Senior Secured Juny 2018 Interest rate PRIME + 1.70% Software Senior Secured Juny 2018 Interest rate PRIME + 1.70% Software Senior Secured December 2017 Interest rate PRIME + 8.25% Software Senior Secured March 2018 Interest rate PRIME + 8.25% Software Software Senior Secured March 2018 Interest rate PRIME + 8.25% Software	Subtotal: Under	1 Year Maturity					9,772	9,761
Corporation (12)(13)		×						
Software Senior Secured July 2017 Interest rate PRIME + 5.50%	Corporation	Software	Senior Secured	December 2017	+ 3.25%			
+ 5.50% or Floor rate of 8.75% Software Senior Secured January 2018 Total CareCloud Corporation Clickfox, Inc. (12)(13) Software Senior Secured December 2017 Senior Secured December 2018 JumpStart Games, Inc. (12)(13) Software Senior Secured March 2018 Floor rate of 11.50% or Floor rate of 11.50% Floor rate of					Floor rate of 6.50%	\$208	204	201
Software Senior Secured January 2018 Interest rate PRIME + 1.70% Software Senior Secured January 2018 Interest rate PRIME + 1.70% Software Senior Secured December 2017 Interest rate PRIME + 8.25% Software Senior Secured December 2018 Interest rate PRIME + 8.25% Software Senior Secured March 2018 Interest rate PRIME + 8.25% Software Senior Secured March 2018 Interest rate PRIME + 8.25% Software Senior Secured March 2018 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME + 8.25% Software Senior Secured October 2016 Interest rate PRIME Software Senior Secured October 2016 Interest rate PRIME Software Senior Secured October 2016 Interest rate PRIME Software Software Senior Secured October 2016 Interest rate PRIME Software Software Software Software Software Software Software Software Software October 2016 Interest rate PRIME Software Software Software Software October 2016 Interest rate PRIME Software Software Software October 2016 Interest rate PRIME Software		Software	Senior Secured	July 2017	+ 5.50%			
Software Senior Secured January 2018 Interest rate PRIME						\$10,000	0.830	9 740
Floor rate of 4.95% \$3,000 2,929 2,884		Software	Senior Secured	January 2018	Interest rate PRIME	ψ10,000	7,037	7,740
Floor rate of 4.95% \$3,000 2,929 2,884					0.00			
Total CareCloud Corporation Senior Secured December 2017 Interest rate PRIME + 8.25%						\$3,000	2 020	2 884
Clickfox, Inc. (12)(13)	Total CareCloud	Corporation			171001 Tate 01 4.95%			
Floor rate of 11.50% \$6,000 6,010 5,948	Clickfox, Inc.	-	Senior Secured	December 2017		ψ13,200	12,7/2	12,023
JumpStart Software Senior Secured March 2018 Interest rate PRIME + 8.25%						*		
Games, Inc. (p.k.a Knowledge Adventure, Inc.) (12)(13) Software Senior Secured October 2016 Floor rate of 11.50% or Floor rate of 11.50% \$11,750	I Ci i	0.0	0 : 0 1	M 1 2010		\$6,000	6,010	5,948
Adventure, Inc.) (12)(13) Software Senior Secured October 2016 Interest rate PRIME + 8.25% or Floor rate of 11.50% \$11,750 11,771 11,709 Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) Mobile Posse, Inc. (12)(13) Senior Secured December 2016 Interest rate PRIME + 7.50% or or or place of 11.50% \$1,356 1,332 1,3	Games, Inc.	Software	Senior Secured	March 2018				
Software Senior Secured October 2016 Interest rate PRIME + 8.25% Or Floor rate of 11.50% \$1,356 1,332 1,332 Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) \$13,106 13,103 13,041 Mobile Posse, Inc. (12)(13) Senior Secured December 2016 Interest rate PRIME + 7.50% Or Or Or Or Or Or Or Or Or Or	Knowledge				or			
Software Senior Secured October 2016 Interest rate PRIME + 8.25% or Floor rate of 11.50% \$1,356 1,332 1,332 Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) \$13,106 13,103 13,041 Mobile Posse, Software Inc. (12)(13) Senior Secured December 2016 Interest rate PRIME + 7.50% or					Floor rate of 11.50%			
+ 8.25% or Floor rate of 11.50% \$1,356 1,332 1,332 Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) Mobile Posse, Software Inc. (12)(13) Senior Secured December 2016 Interest rate PRIME + 7.50% or	(12)(13)					\$11,750	11,771	11,709
Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) Mobile Posse, Software Inc. (12)(13) Floor rate of 11.50% \$1,356 1,332 1,332 Floor rate of 11.50% \$1,356 1,332 1,332 Interest rate of 11.50% \$13,106 13,103 13,041 Interest rate PRIME + 7.50% or		Software	Senior Secured	October 2016				
Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.) Mobile Posse, Software Senior Secured December 2016 Interest rate PRIME + 7.50% or								
(p.k.a Knowledge Adventure, Inc.) \$13,106 13,103 13,041 Mobile Posse, Software Inc. (12)(13) Senior Secured December 2016 Interest rate PRIME + 7.50% or	m . 1 * ~	G *			Floor rate of 11.50%	\$1,356	1,332	1,332
Mobile Posse, Software Senior Secured December 2016 Interest rate PRIME + 7.50% or	(p.k.a Knowledge					\$13 106	13 103	13 041
Inc. (12)(13) + 7.50% or		Software	Senior Secured	December 2016	Interest rate PRIME	ψ13,100	15,105	13,041
		Software	Semor Secured	December 2010	+ 7.50%			
110011460 0110110 4 2,700 - 2,710 - 2,712						\$2,950	2.943	2,972
Neos Software Senior Secured May 2016 Interest rate PRIME \$2,332 2,454 2,444 Geosolutions, + 5.75%		Software	Senior Secured	May 2016	Interest rate PRIME	•		

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

Inc. (12)(13)				or Floor rate of 10.50%			
Poplicus, Inc. (12)(13)	Software	Senior Secured	June 2017	Interest rate PRIME + 5.25%			
				or Floor rate of 8.50%	\$1,500	1,504	1,487
Soasta, Inc. (12)(13)	Software	Senior Secured	February 2018	Interest rate PRIME + 4.75%	\$1,500	1,504	1,407
				or	¢ 15 000	14 267	14 267
	Software	Senior Secured	February 2018	Floor rate of 8.00% Interest rate PRIME + 2.25%	\$15,000	14,367	14,367
				or			
				Floor rate of 5.50%	\$3,500	3,353	3,353
Total Soasta, Inc.					\$18,500	17,720	17,720
Sonian, Inc. (12)(13)	Software	Senior Secured	July 2017	Interest rate PRIME + 7.00%			
				or Elean sets of 10.25%	¢ 5 500	5 450	5 126
StrongView Systems, Inc. (12)	Software	Senior Secured	December 2017	Floor rate of 10.25% Interest rate PRIME + 6.00%	\$5,500	5,450	5,436
				or Floor rate of 9.25%,			
				PIK Interest 3.00%	\$10,000	9,779	9,779
Touchcommerce, Inc. (12)(13)	, Software	Senior Secured	June 2017	Interest rate PRIME + 6.00%			
				or Floor rate of 10.25%	\$5,000	4,903	4,953
Subtotal: 1-5 Yea	ars Maturity			1 1001 1atc 01 10.25%	Ψ3,000	76,838	76,605
Subtotal: Softwar	· · · · · · · · · · · · · · · · · · ·					86,610	86,366
	(/-)					,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

		Type of	Principal		
Portfolio Company	Sub-Industry	InvestnMatth Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Specialty Pharmaceut					
Under 1 Year Maturit	ty				
Cranford Pharmaceuticals,	Specialty Pharmaceuticals	Senior Augustnterest rate LIBOR + 8.25% Secure 2015			
LLC (11)(12)(13)		or Floor rate of 9.50%	\$2,000	\$1,977	\$1,986
Subtotal: Under 1 Yes	ar Maturity			1,977	1,986
1-5 Years Maturity					
Alimera Sciences, Inc. (10)	Specialty Pharmaceuticals	Senior N texur e diterest rate PRIME + 7.65% 2018			
		or Floor rate of 10.90%	\$35,000	34,138	33,429
Cranford Pharmaceuticals, LLC (11)(12)(13)	Specialty Pharmaceuticals	Senior Febru any erest rate LIBOR + 9.55% Secure 2 017 or Floor rate of 10.80%,			
		PIK Interest 1.35%	\$15,644	15,595	15,465
Subtotal: 1-5 Years M	l aturity	10 10 10 10 10 10 10 10 10 10 10 10 10 1	1 -) -	49,733	48,894
Subtotal: Specialty Ph	· · · · · · · · · · · · · · · · · · ·				·
(7.72%)*				51,710	50,880
Surgical Devices					
Under 1 Year Maturit	•				
Transmedics, Inc. (10)(12)	Surgical Devices	Senior Nover Inter est rate FIXED 12.95% Secure 2 015	\$6,061	5,989	5,989
Subtotal: Under 1 Yes	ar Maturity			5,989	5,989
Subtotal: Surgical De	vices (0.91%)*			5,989	5,989
Total Debt Investmen	its (140.23%)*			951,982	923,906

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of			- (2)	(2)
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Equity Investments						
Biotechnology Tools	Dietaskuslass Tasla	E	Duefermed			
NuGEN Technologies, Inc. (13)	Biotechnology Tools	Equity	Preferred Series C	189,394	\$500	\$498
Subtotal: Biotechnology Tools	(0.08%)*				500	498
Communications & Networking						
GlowPoint, Inc. (3)	Communications & Networking	Equity	Common Stock	114,192	102	126
Peerless Network, Inc.	Communications &	Equity	Preferred	ĺ		
	Networking	•	Series A	1,000,000	1,000	7,229
Subtotal: Communications & N	etworking (1.12%)*				1,102	7,355
Consumer & Business Products						
Market Force Information, Inc.		Fanity	Preferred			
warket i ofce information, inc.	Products	Equity	Series B	187,970	500	317
Subtotal: Consumer & Business				,-	500	317
Diagnostic						
Singulex, Inc.	Diagnostic	Equity	Common			
,	U	1 3	Stock	937,998	750	750
Subtotal: Diagnostic (0.11%)*					750	750
_						
Drug Delivery						
AcelRx Pharmaceuticals, Inc. (3)(9)(13)	Drug Delivery	Equity	Common Stock	54,240	109	365
Merrion Pharmaceuticals, Plc	Drug Delivery	Equity	Common	5 1,2 10	107	202
(3)(4)(9)	5 - 1 - 1	17	Stock	20,000	9	_
Neos Therapeutics, Inc. (13)	Drug Delivery	Equity	Preferred	,		
	- ·		Series C	300,000	1,500	1,635
Subtotal: Drug Delivery (0.30%)) *				1,618	2,000

Drug Discovery & Developmen	nt					
Aveo Pharmaceuticals, Inc. (3)(9)(13)	Drug Discovery & Development	Equity	Common Stock	167,864	842	141
Celladon Corporation (3)(13)	Drug Discovery & Development	Equity	Common Stock	105,263	1,000	2,056
Cempra, Inc. (3)	Drug Discovery & Development	Equity	Common Stock	97,931	458	2,303
Cerecor Inc.	Drug Discovery & Development	Equity	Preferred Series B	3,334,445	1,000	922
Dicerna Pharmaceuticals, Inc. (3)(13)	Drug Discovery & Development	Equity	Common Stock	142,858	1,000	2,353
Genocea Biosciences, Inc. (3)	Drug Discovery & Development	Equity	Common Stock	223,463	2,000	1,262
Inotek Pharmaceuticals Corporation (14)	Drug Discovery & Development	Equity	Common Stock	4,523	1,500	_
Insmed, Incorporated (3)	Drug Discovery & Development	Equity	Common Stock	70,771	1,000	845
Paratek Pharmaceuticals, Inc. (p.k.a Transcept	Drug Discovery & Development	Equity	Common Stock		-,000	
Pharmaceuticals, Inc.) (3) Subtotal: Drug Discovery & De	•		Stock	31,580	1,743 10,543	1,158 11,040
Subtotal. Diag Discovery & De	(1.00 %)				10,545	11,040
Electronics & Computer Hardy		Emites	C			
Identiv, Inc. (3)	Electronics & Computer Hardware	Equity	Common Stock	49,097	247	682
Subtotal: Electronics & Compu	•		510 511	.,,,,,,	247	682
	, ,					
Energy Technology						
Glori Energy, Inc. (3)	Energy Technology	Equity	Common Stock	18,208	165	76
SCIEnergy, Inc.	Energy Technology	Equity	Preferred Series 1	385,000	761	22
Subtotal: Energy Technology (Information Services	0.01%)*				926	98
Good Technology Corporation (pka Visto Corporation) (13)	Information Services	Equity	Common Stock	500,000	603	605
Subtotal: Information Services	(0.09%)*		Stock	300,000	603	605
Internet Consumer & Business	Services					
Blurb, Inc. (13)	Internet Consumer &	Equity	Preferred			
Lighteneod DOS Inc (4)(9)	Business Services	Fauity	Series B	220,653	175	265
Lightspeed POS, Inc. (4)(9)	Internet Consumer & Business Services	Equity	Preferred Series C	23,003	250	260
Philotic, Inc.	Internet Consumer & Business Services	Equity	Common Stock	9,023	93	
Progress Financial	Internet Consumer & Business Services	Equity	Preferred Series G	218,351	250	233
Taptera, Inc.		Equity		454,545	150	162

Internet Consumer &	2 Preferred
Business Services	Series B
Subtotal: Internet Consumer & Business Services	

(0.14%)* 918 920

See notes to consolidated financial statements.

Type of

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

		Type of				(2)
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Media/Content/Info						
Everyday Health, Inc.	Media/Content/Info	Equity	Common			
(pka Waterfront Media,			Stock			
Inc.) (3)				97,060	\$1,000	\$1,432
Subtotal: Media/Content/I	nfo (0.22%)*				1,000	1,432
Medical Devices & Equip						
Flowonix Medical	Medical Devices &	Equity	Preferred			
Incorporated	Equipment		Series E	221,893	1,500	1,614
Gelesis, Inc. (5)(13)	Medical Devices &	Equity	LLC Interest			
	Equipment			674,208	425	181
	Medical Devices &	Equity	LLC Interest			
	Equipment			675,676	500	114
	Medical Devices &	Equity	LLC interests			
	Equipment		(Common)	674,208	_	31
Total Gelesis, Inc.				2,024,092	925	326
Medrobotics Corporation	Medical Devices &	Equity	Preferred			
(13)	Equipment		Series E	136,798	250	149
	Medical Devices &	Equity	Preferred			
	Equipment		Series F	73,971	155	167
Total Medrobotics						
Corporation				210,769	405	316
Novasys Medical, Inc.	Medical Devices &	Equity	Preferred			
	Equipment		Series D-1	4,118,444	1,000	
Optiscan Biomedical,	Medical Devices &	Equity	Preferred			
Corp. (5)(13)	Equipment		Series B	6,185,567	3,000	455
	Medical Devices &	Equity	Preferred			
	Equipment		Series C	1,927,309	655	138
	Medical Devices &	Equity	Preferred			
	Equipment		Series D	55,103,923	5,257	5,260
Total Optiscan	• •					
Biomedical, Corp				63,216,799	8,912	5,853
Oraya Therapeutics, Inc.	Medical Devices &	Equity	Preferred			
	Equipment		Series 1	1,086,969	500	
Subtotal: Medical Devices					13,242	8,109

Software						
Atrenta, Inc.	Software	Equity	Preferred			
	g 0	.	Series C	1,196,845	986	1,745
	Software	Equity	Preferred	(25.512	5 00	1 100
Total Atrenta, Inc			Series D	635,513 1,832,358	508 1,494	1,109 2,854
Box, Inc. (13)(14)	Software	Equity	Preferred	1,032,330	1,494	2,034
DOX, IIIC.	Software	Equity	Series B	271,070	251	5,747
	Software	Equity	Preferred	271,070	201	2,7 17
		-4,	Series C	589,844	872	12,506
	Software	Equity	Preferred			
			Series D	158,133	500	3,352
	Software	Equity	Preferred			
			Series D-1	186,766	1,694	3,960
	Software	Equity	Preferred	220 551	• • • • •	4.600
	C - 64	F	Series D-2	220,751	2,001	4,680
	Software	Equity	Preferred Series E	20 102	500	810
Total Box, Inc			Series E	38,183 1,464,747	5,818	31,055
CapLinked, Inc.	Software	Equity	Preferred	1,404,747	3,010	31,033
Capelinked, Inc.	Software	Equity	Series A-3	53,614	51	79
ForeScout Technologies,	Software	Equity	Preferred	23,011	0.1	, ,
Inc.		1	Series D	319,099	398	519
HighRoads, Inc.	Software	Equity	Preferred			
		• •	Series B	190,170	307	228
WildTangent, Inc. (13)	Software	Equity	Preferred			
			Series 3	100,000	402	228
Subtotal: Software (5.31%)	(b)*				8,470	34,963
Consister Dhamas assetiasta						
Specialty Pharmaceuticals QuatRx Pharmaceuticals	Specialty	Equity	Preferred			
Company	Pharmaceuticals	Equity	Series E	241,829	750	
Company	Specialty	Equity	Preferred	241,02)	730	
	Pharmaceuticals	Equity	Series E-1	26,955	_	_
	Specialty	Equity	Preferred	_ 0,2 0 0		
	Pharmaceuticals	1 7	Series G	4,667,636	_	
Total QuatRx						
Pharmaceuticals Company				4,936,420	750	_
Subtotal: Specialty Pharm	aceuticals (0.00%)*				750	_
a : 15 :						
Surgical Devices	Cumical Davisco	Emite	Duafamad			
Gynesonics, Inc. (13)	Surgical Devices	Equity	Preferred Series B	210 209	250	101
	Surgical Devices	Equity	Preferred	219,298	250	101
	Suigical Devices	Equity	Series C	656,538	282	186
	Surgical Devices	Equity	Preferred	050,550	202	100
	2 0 1000	-1	Series D	1,991,157	712	1,073
Total Gynesonics, Inc.				2,866,993	1,244	1,360
				2,000,773	1,477	1,500
Transmedics, Inc.	Surgical Devices	Equity		88,961	1,100	353

Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC - Form 10-Q

		Preferred Series B			
Surgical Devices	Equity	Preferred			
		Series C	119,999	300	180
Surgical Devices	Equity	Preferred			
		Series D	260,000	650	1,071
Total Transmedics, Inc.			468,960	2,050	1,604
Subtotal: Surgical Devices (0.45%)*				3,294	2,964
Total: Equity Investments (10.89%)*				44,463	71,733

See notes to consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

Portfolio Compony	Cub Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost(2)	Value ⁽³⁾
Portfolio Company Warrant Investments	Sub-Industry	mvestment(1)	Series	Shares	Cost	v arue(3)
Biotechnology Tools						
Bioteciniology Tools	Biotechnology Tools	Warrant	Preferred			
Labcyte, Inc. (13)	Diotectifiology 1001s	vv arraint	Series C	1,127,624	\$323	\$ 354
Subtotal: Biotechnology Tools ((0.05%)*		Series C	1,127,024	323	354
Subtotal. Diotectifiology Tools ((0.03 /0)				323	JJ T
Communications & Networking	•					
Intelepeer, Inc. (13)	Communications &	Warrant	Preferred			
	Networking	,, 6110110	Series C	117,958	102	18
OpenPeak, Inc.	Communications &	Warrant	Common	117,500	102	10
- F,	Networking		Stock	108,982	149	104
PeerApp, Inc.	Communications &	Warrant	Preferred	,		
117	Networking		Series B	298,779	61	45
Peerless Network, Inc.	Communications &	Warrant	Preferred			
	Networking		Series A	135,000	95	844
Ping Identity Corporation	Communications &	Warrant	Preferred			
	Networking		Series B	1,136,277	52	183
SkyCross, Inc. (13)	Communications &	Warrant	Preferred			
	Networking		Series F	9,762,777	394	
Spring Mobile Solutions, Inc.	Communications &	Warrant	Preferred			
	Networking		Series D	2,834,375	418	426
Subtotal: Communications & No	etworking (0.25%)*				1,271	1,620
Consumer & Business Products						
Antenna79 (p.k.a. Pong	Consumer &		Preferred			
Research Corporation) (13)	Business Products	Warrant	Series A	1,662,441	228	202
Intelligent Beauty, Inc. (13)	Consumer &	Warrant	Preferred			
	Business Products		Series B	190,234	230	327
IronPlanet, Inc.	Consumer &	Warrant	Preferred			
	Business Products		Series D	1,155,821	1,077	1,067
Market Force Information, Inc.	Consumer &	Warrant	Preferred			
(12)	Business Products		Series A	99,286	24	21
The Neat Company (13)	Consumer &	Warrant	Preferred	5.40. 5.40	267	1 = 1
	Business Products		Series C-1	540,540	365	451
Subtotal: Consumer & Business	Products (0.31%)*				1,924	2,068

Diagnostic						
Navidea Biopharmaceuticals,			Common			
Inc. (pka Neoprobe) (3)(13)	Diagnostic	Warrant	Stock	333,333	244	75
Subtotal: Diagnostic (0.01%)*					244	75
Drug Delivery						
AcelRx Pharmaceuticals, Inc.	Drug Delivery	Warrant	Common			
(3)(9)(13)			Stock	176,730	786	420
Alexza Pharmaceuticals, Inc. (3)	Drug Delivery	Warrant	Common			
			Stock	37,639	645	_
BIND Therapeutics, Inc. (3)(13)	Drug Delivery	Warrant	Common			
			Stock	71,359	367	6
BioQuiddity Incorporated	Drug Delivery	Warrant	Common			
			Stock	459,183	_1	1
Celator Pharmaceuticals, Inc. (3)	Drug Delivery	Warrant	Common			
			Stock	158,006		